11. EUROPEAN LUPUS MEETING
DÜSSELDORF 21.-24. MARCH 2018

Final Program
This meeting is endorsed by

[Image of EULAR logo]

[Image of DGRh Rheumazentrum Rhein-Ruhr logo]
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome message</td>
<td>4</td>
</tr>
<tr>
<td>SLEuro Board</td>
<td>5</td>
</tr>
<tr>
<td>Committees</td>
<td>6</td>
</tr>
<tr>
<td>Program overview</td>
<td>7</td>
</tr>
<tr>
<td>Pre-Meeting Course</td>
<td>11</td>
</tr>
<tr>
<td>Scientific program</td>
<td></td>
</tr>
<tr>
<td>Wednesday, March 21</td>
<td>12</td>
</tr>
<tr>
<td>Thursday, March 22</td>
<td>14</td>
</tr>
<tr>
<td>Friday, March 23</td>
<td>22</td>
</tr>
<tr>
<td>Poster sessions</td>
<td>30</td>
</tr>
<tr>
<td>Post Meeting Course</td>
<td>54</td>
</tr>
<tr>
<td>Scientific information</td>
<td></td>
</tr>
<tr>
<td>Abstract book</td>
<td>55</td>
</tr>
<tr>
<td>Fishbowls</td>
<td>56</td>
</tr>
<tr>
<td>Guidelines for chairpersons and speakers</td>
<td>57</td>
</tr>
<tr>
<td>Oral communications and poster display</td>
<td>57</td>
</tr>
<tr>
<td>Best papers</td>
<td>57</td>
</tr>
<tr>
<td>E-Posters and discussion</td>
<td>58</td>
</tr>
<tr>
<td>CME Accreditation</td>
<td>59</td>
</tr>
<tr>
<td>General information</td>
<td></td>
</tr>
<tr>
<td>Congress venue</td>
<td>60</td>
</tr>
<tr>
<td>Floorplan</td>
<td>62</td>
</tr>
<tr>
<td>Useful information</td>
<td>64</td>
</tr>
<tr>
<td>Registration information</td>
<td>66</td>
</tr>
<tr>
<td>Social Media</td>
<td>67</td>
</tr>
<tr>
<td>Accommodation</td>
<td>68</td>
</tr>
<tr>
<td>Sponsored sessions</td>
<td>69</td>
</tr>
<tr>
<td>Authors index</td>
<td>75</td>
</tr>
<tr>
<td>SLEuro Society</td>
<td>87</td>
</tr>
<tr>
<td>Acknowledgements and industry support</td>
<td>88</td>
</tr>
</tbody>
</table>
Dear
Artist, Biostatistician, Colleague, Drug Developer, Epidemiologist, Fellow, Friend, Geneticist, Journalist, Lupologist, Medical Representative, Patient, Pathologist, Psychologist, Publisher, Researcher, Scientist, Speaker, Sponsor, Support Group, Teacher

If you are delighted to learn something new every day just by taking care of patients and if you are enthusiastic about discovering something unexpected day by day and if you are keen to learn from other specialities in- and outside of medicine and if you like good friendship with your greatest competitor and if you are convinced that you can learn a lot from failures and if you welcome global collaborations without borders,

you are probably an avowed lupus enthusiast, and we are looking forward to welcoming you in Düsseldorf on the occasion of the 11th European Lupus Meeting in March 2018 (21st-24th).

A mixture of the above listed options connects us to the fascinating disease lupus and convinced us that a multifaceted fusion of clinical and basic science together with new promising data from clinical trials will make an interesting and challenging content for Düsseldorf meeting.

The 11th European Lupus Meeting is the first conference of the newly founded European Lupus Society. It will be our pleasure to open up the space for open and fruitful discussions about future developments in the field.

Topics may be “International Collaborations” and “Young Academics in Lupus Research”, who we invite to be actively involved in the scientific programme. If you like to experience a synthesis of traditional, modern and future perspectives of medicine and science, Düsseldorf will be your town to visit in March 2018.

Following the meetings in extraordinary cities like Venice (2016) and Melbourne (2017), Düsseldorf, a modern city marvellously situated on the river Rhine with a special passion for art and fashion, full of very warm-hearted and sociable people will welcome you.

Düsseldorf is a city of short distances, directly connected to most European cities, as well as to the USA and Asia.

I am looking forward to welcoming you in Düsseldorf!

Matthias Schneider
President European Lupus Society
BOARD

**PRESIDENT**
Matthias Schneider (*Düsseldorf, Germany*)

**PRESIDENT ELECT**
Frédéric Houssiau (*Bruxelles, Belgium*)

**GENERAL SECRETARY**
Elisabet Svenungsson (*Stockholm, Sweden*)

**TREASURER**
Andrea Doria (*Padua, Italy*)

**MEMBERS**

Anisur Rahman (*London, UK*)
Dimitrios Boumpas (*Athens, Greece*)
Ricard Cervera (*Barcelona, Spain*)
Carlo Chizzolini (*Geneva, Switzerland*)
Nathalie Costedoat-Chalumeau (*Paris, France*)
László Czirják (*Pecs, Hungary*)
Luis Pedro Sousa Ines (*Coimbra, Portugal*)
Ronald Van Vollenhoven (*Amsterdam, The Netherlands*)

SECRETARIAT

**EUROPEAN LUPUS SOCIETY**
Via G. Ripamonti, 129
20141 Milan (Italy)
Phone +39 02 566011
Fax +39 02 70048578
SLEuroSecretariat@aimgroup.eu
# Committees

## CONGRESS CHAIRPERSON
M. Schneider (Düsseldorf, Germany)

## CONGRESS SECRETARY
J. Mucke (Düsseldorf, Germany)

## PAST CHAIRS
D. Boumpas (Athens, Greece)
S. Bombardieri (Pisa, Italy)
R. Cervera (Barcelona, Spain)
A. Doria (Padua, Italy)
D. Isenberg (London, UK)
J. Kalden (Erlangen, Germany)
C. Kallenberg (Amsterdam, The Netherlands)
M. Khamashta (Dubai, UAE)
H.M. Moutsopoulos (Athens, Greece)
J. Smolen (Vienna, Austria)
A. Tincani (Brescia, Italy)
C. Vasconcelos (Porto, Portugal)

## LOCAL SCIENTIFIC COMMITTEE
H. Anders (Munich, Germany)
M. Aringer (Dresden, Germany)
G. Chehab (Düsseldorf, Germany)
T. Dörner (Berlin, Germany)
R. Fischer-Betz (Düsseldorf, Germany)
F. Hiepe (Berlin, Germany)
H. Lorenz (Heidelberg, Germany)
A. Schwarting (Mainz, Germany)
C. Specker (Essen, Germany)
R. Voll (Freiburg, Germany)
S. Vordenbäumen (Düsseldorf, Germany)

## INTERNATIONAL SCIENTIFIC COMMITTEE
N. Agmon-Levin (Tel-Hashomer, Israel)
M. Alarcon-Riquelme (Granada, Spain)
Z. Amoura (Paris, France)
L. Arnaud (Strasbourg, France)
Jo H.M. Berden (Nijmegen, The Netherlands)
G. Bertias (Heraklion, Greece)
D. Boumpas (Athens, Greece)
I. Bruce (Manchester, UK)
R. Cervera (Barcelona, Spain)
C. Chizzolini (Geneva, Switzerland)
N. Costedoat-Chalumeau (Paris, France)
L. Czirjak (Pecs, Hungary)
D. D’Cruz (London, UK)
A. Doria (Padua, Italy)
R. Furie (New York, USA)
M.E. Gershwin (Davis, USA)
F. Houssiau (Brussels, Belgium)
D. Isenberg (London, UK)
S. Jacobsen (Copenhagen, Denmark)
D. Jayne (Cambridge, UK)
M. Khamashta (Dubai, UAE)
X. Mariette (Paris, France)
M. Mosca (Pisa, Italy)
J. Pego-Reigosa (Vigo, Spain)
B. Pons-Estel (Rosario, Argentina)
A. Rahman (London, UK)
L. Rönnblom (Uppsala, Sweden)
G. Ruiz-Irastorza (Barakaldo, Spain)
Y. Shoenfeld (Tel-Hashomer, Israel, Saint Petersburg, Russia)
L. Sousa Ines (Coimbra, Portugal)
E. Svenungsson (Stockholm, Sweden)
M. Tektonidou (Athens, Greece)
A. Tincani (Brescia, Italy)
M. Urowitz (Toronto, Canada)
R. Van Vollenhoven (Amsterdam, The Netherlands)
C. Vasconcelos (Porto, Portugal)
Program Overview

Wednesday, 21 March 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>3A ROOM</th>
<th>3D ROOM</th>
<th>Building ZOMII</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-12:15</td>
<td></td>
<td></td>
<td>Pre-Meeting Course* (Conference Room 3)</td>
</tr>
<tr>
<td>12:15-13:00</td>
<td></td>
<td></td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00-15:00</td>
<td></td>
<td></td>
<td>Pre-Meeting Course* (Conference Room 3+7)</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-18:30</td>
<td></td>
<td></td>
<td>Exhibition Opening</td>
</tr>
<tr>
<td>18:30-20:00</td>
<td>When it all begins …</td>
<td>Therapeutic strategies</td>
<td></td>
</tr>
<tr>
<td>20:00-21:00</td>
<td></td>
<td></td>
<td>Welcome Cocktail</td>
</tr>
</tbody>
</table>

*Not Accredited

KEY LEGEND

- PRE MEETING COURSE
- CONGRESS SESSIONS AND ORAL PRESENTATIONS Room 3A
- CONGRESS SESSIONS AND ORAL PRESENTATIONS Room 3D
- INDUSTRY SPONSORED SYMPOSIA
- FISHBOWL DISCUSSION ROUNDS
- POST MEETING COURSE
# Program Overview

## Thursday, 22 March 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>3A ROOM</th>
<th>3D ROOM</th>
<th>POSTER AREA</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>Prediction &amp; prevention</td>
<td>Lupus nephritis</td>
<td>ROY LICHTENSTEIN</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20-12:00</td>
<td>Immunopathogenesis I</td>
<td>APS</td>
<td></td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Lunch and E-Poster Discussion*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>INDUSTRY-SPONSORED SYMPOSIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15-16:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:20-16:50</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:50-18:30</td>
<td>Longterm outcome</td>
<td>Reproduction</td>
<td></td>
</tr>
<tr>
<td>18:30-19:30</td>
<td>SLEuro General Assembly</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Not Accredited

## Fishbowl/Open Chair - discussion rounds

- All lupus patients should be on antimalarials!
- Treatment of lupus nephritis without glucocorticoids?
- Minimal clinical data set for routine care/research
- Improving trial design
- Patient empowerment!

## KEY LEGEND

- **PRE MEETING COURSE**
  - CONGRESS SESSIONS AND ORAL PRESENTATIONS Room 3A
  - INDUSTRY SPONSORED SYMPOSIA
  - FISHBOWL DISCUSSION ROUNDS
  - POST MEETING COURSE
- **CONGRESS SESSIONS AND ORAL PRESENTATIONS Room 3D**
- **REPRODUCTION**
## Program Overview

### Friday, 23 March 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>3A ROOM</th>
<th>3D ROOM</th>
<th>POSTER AREA ROY LICHTENSTEIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td><strong>INDUSTRY-SPONSORED SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Biomarker &amp; indices</td>
<td>Supportive therapies</td>
<td></td>
</tr>
<tr>
<td>10:30-10:50</td>
<td><em>Coffee break</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50-12:30</td>
<td>Maintenance therapy</td>
<td>Immunopathogenesis II</td>
<td></td>
</tr>
<tr>
<td>12:30-14:00</td>
<td><strong>Lunch and E-Poster Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-15:00</td>
<td><strong>INDUSTRY-SPONSORED SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15-16:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:20-16:50</td>
<td><em>Coffee break</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:50-18:40</td>
<td>New therapeutic candidates</td>
<td>PRO</td>
<td></td>
</tr>
<tr>
<td>18:40-19:00</td>
<td><strong>CLOSING CEREMONY</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Not Accredited

## Fishbowl/Open Chair - discussion rounds

- Measuring lupus disease activity in daily clinical practice: challenges and unmet needs (based on cases)
- Who takes care of lupus patients?
- B cell depleting treatment in lupus
- Fatigue in lupus: feature of the disease or conditioning by patience “education”? How to improve lupus outcome?

## KEY LEGEND

- **PRE MEETING COURSE**
- **CONGRESS SESSIONS AND ORAL PRESENTATIONS** Room 3A
- **CONGRESS SESSIONS AND ORAL PRESENTATIONS** Room 3D
- **INDUSTRY SPONSORED SYMPOSIA**
- **FISHBOWL DISCUSSION ROUNDS**
- **POST MEETING COURSE**
### Saturday, 24 March 2018

<table>
<thead>
<tr>
<th>hrs</th>
<th>3A ROOM</th>
</tr>
</thead>
</table>
| 10:00-11:15 | **Post meeting course***  
“Development of targeted therapies in rheumatology” |
| 11:15-11:45 | **Coffee break**                           |
| 11:45-13:00 | **Post meeting course***  
“Development of targeted therapies in rheumatology” |

*Not Accredited*
Pre-Meeting Course

WEDNESDAY 21 MARCH 2018

The Pre-Meeting Course can only be attended by Trainees/Fellows

Conference Room 3 - Building ZOMII
10:00-15:00  PRE-MEETING COURSE
10:00-11:00  Diagnosis of SLE and SLE mimics
             M. Aringer (Dresden, Germany)

11:00-11:15  Break
11:15-12:15  Therapeutic strategies in SLE
             F. Hiepe (Berlin, Germany)

12:15-13:00  Lunch

The participants will be divided in two groups according to their preferences.

Conference Room 3 - Building ZOMII
13:00-15:00  Immunofluorescence microscopy
             C. Specker (Essen, Germany)

Conference Room 7 - Building ZOMII
13:00-15:00  Capillary microscopy
             O. Sander (Düsseldorf, Germany)

No CME activity
Scientific Program

WEDNESDAY 21 MARCH 2018

Room 3A
17:00-18:30
OPENING CEREMONY
GREETINGS
OPENING LECTURE: one-net-show
A. Paetzel (Düsseldorf, Germany), T. Schönauer (Düsseldorf, Germany)

Room 3A
18:30-20:00
WHEN IT ALL BEGINS...
Chairs: S. Bombardieri (Pisa, Italy), M. Schneider (Düsseldorf, Germany)

18:30-18:50
New SLE classification criteria: challenges and opportunities
M. Aringer (Dresden, Germany)

18:50-19:10
Which lupus do you have? Phenotyping the disease
M. Urowitz (Toronto, Canada)

19:10-19:30
Gene profiling studies in SLE. What have we learned?
G. Bertsias (Heraklion, Greece)

19:30-19:40
ROBUST STRATIFICATION OF LUPUS BASED ON LONGITUDINAL GENE EXPRESSION DATA AND DISEASE ACTIVITY PATTERNS
D. Toro Dominguez¹, P. Carmona Saez¹, M.E. Alarcón-Riquelme¹²
(¹Granada, Spain, ²Stockholm, Sweden)

19:40-19:50
MOLECULAR STRATIFICATION OF AUTOIMMUNE DISEASES BASED ON EPIGENETIC PROFILES
G. Barturen¹, M. Kerick¹, D. Alvarez-Errico², R. Quintares¹, E. Carnero¹, D. Gemperline³, E. Dow³, L. Beretta⁴, J.O. Pers⁵, Y. Renadineau⁶, J. Frostegard⁶, M. Juarez²¹, Clinical Consortium¹, Flow Cytometry Group¹, S. Rao⁸, C. Chamberlain⁷, J. Wojcik⁹, A. Segura¹, J. Martin¹, E. Ballestar², M.E. Alarcón-Riquelme¹
(¹Granada, Spain, ²Barcelona, Spain, ³Indianapolis, USA, ⁴Milan, Italy, ⁵Brest, France, ⁶Solna, Sweden, ⁷Slough, UK, ⁸Boston, USA, ⁹Geneva, Switzerland)

19:50-20:00
MCTD AND SLE: SIMILARITIES AND DIFFERENCES
S. Reiseter, Ø. Molberg, R. Gunnarsson, K. Lerang
(Oslo, Norway)
### Room 3D

**18:30-20:00**  
**THERAPEUTIC STRATEGIES**  
Chairs: C. Kallenberg (Groningen, The Netherlands), E. Svenungsson (Stockholm, Sweden)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30-18:50</td>
<td>Targeted therapies - how do they influence outcome</td>
<td>J. Smolen (Vienna, Austria)</td>
</tr>
<tr>
<td>18:50-19:10</td>
<td>Definitions of remission in SLE</td>
<td>R. Van Vollenhoven (Amsterdam, The Netherlands)</td>
</tr>
<tr>
<td>19:10-19:30</td>
<td>New therapeutic strategies in lupus management</td>
<td>A. Doria (Padua, Italy)</td>
</tr>
<tr>
<td>19:50-20:00</td>
<td>TARGETING PLASMA CELLS AND THEIR PRECURSORS BY IMMUNOABLATION VERSUS BORTEZOMIB PLUS RITUXIMAB IN SYSTEMIC LUPUS ERYTHEMTOSUS</td>
<td>T. Alexander, B. Hoyer, Q. Cheng, L. Khodadadi, A. Taddeo, J. Klotsche, A. Thiel, G. Burmester, A. Radbruch, R. Arnold, F. Hiepe (Berlin, Germany)</td>
</tr>
</tbody>
</table>

**20:00-21:00**  
**Welcome Cocktail in the Exhibition Area**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:50</td>
<td><strong>Pre-Lupus: can we predict and prevent SLE?</strong></td>
<td>M. Mosca (Pisa, Italy)</td>
</tr>
<tr>
<td>08:50-09:10</td>
<td><strong>Lupus flares: how to predict and prevent?</strong></td>
<td>L.P. Sousa Ines (Coimbra, Portugal)</td>
</tr>
<tr>
<td>09:10-09:30</td>
<td><strong>Damage accrual: risk stratification and prevention</strong></td>
<td>I. Bruce (Manchester, UK)</td>
</tr>
<tr>
<td>09:30-09:40</td>
<td><strong>Validation of Remission and Lupus Low Disease Activity State as Predictors of Organ Damage in SLE</strong></td>
<td>M. Petri, D. Goldman, L. Magder (Baltimore, USA)</td>
</tr>
<tr>
<td>09:40-09:50</td>
<td><strong>Development and Validation of a Score to Predict the Risk of Severe Infection in SLE</strong></td>
<td>B. Segura¹, I. Rúa-Figueroa¹, J.M. Pego-Reigosa², V. Del Campo-Pérez², D. Isenberg³, A. Rahman³ (¹Las Palmas de Gran Canaria, Spain, ²Vigo, Spain, ³London, UK)</td>
</tr>
<tr>
<td>09:50-10:00</td>
<td><strong>Soluble Urokinase Plasminogen Activator Receptor (SUPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort</strong></td>
<td>H. Enocsson¹, L. Wirestam¹, J. Wetterö¹, T. Skogh¹, The SLICC Group, I. Bruce², C. Sjöwall¹ (¹Linköping, Sweden, ²Manchester, UK)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08:30-10:00</td>
<td><strong>LUPUS NEPHRITIS</strong></td>
<td></td>
</tr>
<tr>
<td>Chairs:</td>
<td>R. Furie (New York, USA), D. Jayne (Cambridge, UK)</td>
<td></td>
</tr>
<tr>
<td>08:30-08:50</td>
<td><strong>New trends in the treatment of lupus nephritis</strong></td>
<td></td>
</tr>
<tr>
<td>F. Houssiau</td>
<td>(Brussels, Belgium)</td>
<td></td>
</tr>
<tr>
<td>08:50-09:10</td>
<td><strong>How to manage “refractory lupus nephritis”?</strong></td>
<td></td>
</tr>
<tr>
<td>H.J. Anders</td>
<td>(Munich, Germany)</td>
<td></td>
</tr>
<tr>
<td>09:10-09:30</td>
<td><strong>Nephritogenicity of anti-nucleosome autoantibodies in lupus</strong></td>
<td></td>
</tr>
<tr>
<td>Jo H.M. Berden</td>
<td>(Nijmegen, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>09:30-09:40</td>
<td><strong>CHANGE IN CLINICAL, HISTOLOGICAL PRESENTATION AND PROGNOSIS OF LUPUS NEPHRITIS DURING THE LAST 50 YEARS</strong></td>
<td></td>
</tr>
<tr>
<td>G. Moroni¹,</td>
<td>M. Gatto², P.G. Vercellone¹, S. Quaglini², F. Raffiotta¹, M. Zen²,</td>
<td></td>
</tr>
<tr>
<td>M. Gatto²,</td>
<td>F. Pieruzzi¹, V. Binda¹, P. Messa¹, R.A. Sinico¹, A. Doria²</td>
<td></td>
</tr>
<tr>
<td>P. Gatto²,</td>
<td>(¹Milan, Italy, ²Padua, Italy)</td>
<td></td>
</tr>
<tr>
<td>S. Quaglini²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F. Raffiotta¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. Zen²,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F. Pieruzzi¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V. Binda¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. Messa¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R.A. Sinico¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Doria²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:40-09:50</td>
<td><strong>EXOSOMES TARGET RENAL TUBULAR EPITHELIAL CELLS TRANSFERRING INFLAMMATORY EPSTEIN–BARR VIRUS-ENCODED SMALL RNA (EBER1) IN LUPUS NEPHRITIS PATIENTS</strong></td>
<td></td>
</tr>
<tr>
<td>S.R. Baglio¹,</td>
<td>N. Masoumi¹, M.W. Tsang-A-Sjoe¹, M.A. Van Eijndhoven¹, K.M. Heutinck¹,</td>
<td></td>
</tr>
<tr>
<td>N. Masoumi¹,</td>
<td>E.S. Jordanova¹, R.J. Ten Berge¹, K. Grundberg², R.M. Schifferer³, J.</td>
<td></td>
</tr>
<tr>
<td>M.W. Tsang-A-Sjoe¹,</td>
<td>Van Den Wetering¹, K. De Wildt¹, S.M. Verkuijlen¹, J. Roelofs¹, I.E.</td>
<td></td>
</tr>
<tr>
<td>M.A. Van Eijndhoven¹,</td>
<td>Bultink¹, J.M. Middeldorp¹, A.E. Voskuyl¹, D.M. Pegtel¹</td>
<td></td>
</tr>
<tr>
<td>K.M. Heutinck¹,</td>
<td>(¹Amsterdam, The Netherlands, ²Nijmegen, The Netherlands, ³Utrecht, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>E.S. Jordanova¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R.J. Ten Berge¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K. Grundberg²,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R.M. Schifferer³,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J. Van Den Wetering¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K. De Wildt¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.M. Verkuijlen¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J. Roelofs¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.E. Bultink¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J.M. Middeldorp¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A.E. Voskuyl¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D.M. Pegtel¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:50-10:00</td>
<td><strong>ANTIRENAL CD4+ T CELLS ARISE IN LUPUS NEPHRITIS, ARE MAINLY OF THE TH1 PHENOTYPE, ARE ONLY PARTIALLY CONTROLLED BY THEIR REGULATORY COUNTERPARTS AND INVADE THE INFLAMED KIDNEYS</strong></td>
<td></td>
</tr>
<tr>
<td>S. Tesch¹,</td>
<td>D. Abdirama¹, A.S. Grießbach¹, J.Y. Humrich², A. Scheffold¹, A. Radbruch¹,</td>
<td></td>
</tr>
<tr>
<td>D. Abdirama¹,</td>
<td>G.R. Burmester¹, K.U. Eckardt¹, F. Hiepe¹, G. Riemekasten¹, P. Enghard¹</td>
<td></td>
</tr>
<tr>
<td>A.S. Grießbach¹,</td>
<td>(¹Berlin, Germany, ²Lübeck, Germany)</td>
<td></td>
</tr>
<tr>
<td>J.Y. Humrich²,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Scheffold¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Radbruch¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G.R. Burmester¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K.U. Eckardt¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F. Hiepe¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Riemekasten¹,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. Enghard¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
</tbody>
</table>
Room 3A
10:20-12:00 IMMUNOPATHOGENESIS I
Chairs: J. Kalden (Erlangen, Germany), H. Lorenz (Heidelberg, Germany)

10:20-10:40 Immunopathogenic mechanisms driving lupus
T. Dörner (Berlin, Germany)

10:40-11:00 The interaction between pDC and the adaptive immune system
L. Rönnblom (Uppsala, Sweden)

11:00-11:20 Antimicrobial peptides in SLE pathogenesis
C. Chizzolini (Geneva, Switzerland)

11:20-11:30 OX40/OX40L AXIS IMPAIRS FOLLICULAR AND NATURAL REGULATORY T CELL FUNCTION IN HUMAN SYSTEMIC LUPUS
C. Richez¹, J.F. Augusto², E. Lazaro¹, N. Gensous¹, I. Douchet¹, C. Contin-Bordes¹, P. Blanco¹
(¹Bordeaux, France, ²Angers, France)

11:30-11:40 AUTOANTIBODIES AGAINST HUMAN SERUM ALBUMIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
J. Nehring¹, L.A. Schirmbeck¹, J. Friebus-Kardash¹, D. Dubler¹, U. Huynh-Do³, C. Chizzolini⁴, C. Ribi⁵, M. Trendelenburg¹
(¹Basel, Switzerland, ²Essen, Germany, ³Bern, Germany, ⁴Geneva, Switzerland, ⁵Lausanne, Switzerland)

11:40-11:50 MICROPARTICLES WITH MITOCHONDRIAL MOLECULES AND IMMUNOGLOBULINS ASSOCIATE WITH ACTIVE DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS
F. Mobarrez¹, E. Fuzzi¹, I. Gunnarsson¹, D. Pisetsky², E. Svenungsson¹
(¹Stockholm, Sweden, ²Durham, USA)

11:50-12:00 NEUTROPHIL EXTRACELLULAR TRAPS MARKERS ARE ELEVATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
I. Jeremic, O. Djuric, B. Bonaci-Nikolic
(Belgrade, Serbia)
Room 3D

10:20-12:00 APS

Chairs: M. Khamashta (Dubai, UAE), H.M. Moutsopoulos (Athens, Greece)

10:20-10:40 Treatment of APS - towards 2018
N. Agmon-Levin (Tel-Hashomer, Israel)

10:40-11:00 Catastrophic antiphospholipid syndrome: an update
R. Cervera (Barcelona, Spain)

11:00-11:20 Neurologic manifestations: SLE versus APS
C. Vasconcelos (Porto, Portugal)

11:20-11:30 REAL LIFE SINGLE CENTRE RESULTS ON RITUXIMAB TREATMENT OF PATIENTS WITH PRIMARY AND LUPUS ASSOCIATED ANTIPHOSPHOLIPID SYNDROME
E. Kiss, A. Szappanos, A. Wiedemann, A. Balogh, M. Szabo, G. Poor (Budapest, Hungary)

11:30-11:40 PLASMA SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 IS ELEVATED IN PATIENTS WITH THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME
Y. Molad¹, Y. Edel¹², E. Pokroy-Shapira¹², S. Oren¹², A. Dortort¹², Y. Pri-Paz Basson, T. Shohat¹², V. Kliminski¹²
(¹Petah Tikva, Israel, ²Tel Aviv, Israel)

11:40-11:50 MICROANGIOPATHIC MANIFESTATIONS OF THE PRIMARY ANTIPHOSPHOLIPID SYNDROME
J. Zhao, Y. Sun, Q. Wang, M. Li, X. Zeng (Beijing, China)

11:50-12:00 CEREBRAL HYPOPERFUSION DETECTED BY PERFUSION-WEIGHED MRI MAY ASSIST THE DIAGNOSIS OF PRIMARY DIFFUSE NEUROPSYCHIATRIC LUPUS ERYTHEMATOSUS
E. Papadaki¹, A. Fanourakis², E. Kavroulakis¹, D. Karageorgou¹, P. Sidiropoulos¹, G. Beretsias¹, P. Simos¹, D. Boumpas²
(¹Heraklion, Greece, ²Athens, Greece)

12:00-13:30 Lunch and E-Poster Discussion
Room 3A
13:30-15:00  INDUSTRY - SPONSORED SYMPOSIUM  (see page n. 69)

Poster Area
15:15-16:15  FISHBOWL AND OPEN CHAIR - DISCUSSION ROUNDS  (rules at page 56)

Fishbowl 1  All lupus patients should be on antimalarials!
Moderator: R. Voll (Freiburg, Germany)
Discussants:
J. Bakshi (London, UK), I. Bruce (Manchester, UK),
R. Van Vollenhoven (Amsterdam, The Netherlands),
W. Zacouris-Verweij (Haarlem, The Netherlands)

Fishbowl 2  Treatment of lupus nephritis without glucocorticoids?
Moderator: H.J. Anders (Münich, Germany)
Discussants:
F. Farinha (London, UK), F. Houssiau (Brussels, Belgium)
D. Jayne (Cambridge, UK), Z. Osmani (The Hague, The Netherlands)

Fishbowl 3  Minimal clinical data set for routine care/research?
Moderator: H. Lorenz (Heidelberg, Germany)
Discussants:
L. Czirják (Pecs, Hungary), Y. Norton (Coseley, UK)
J.M. Pego-Reigosa (Vigo, Spain), M. Siekierka-Harreis (Düsseldorf, Germany)
Fishbowl 4  **Improving trial design**
Moderator: M. Aringer (Dresden, Germany)
*Discussants:*
R. Cervera (Barcelona, Spain), M. Gatto (Padua, Italy),
K. Lerstrøm (Farum, Denmark), R. Tummala (Gaithersburg, USA)

Fishbowl 5  **Patient empowerment!**
Moderator: G. Chehab (Düsseldorf, Germany)
*Discussants:*
J. Andersen (Knebel, Denmark), I. Haase (Düsseldorf, Germany)
M. Mosca (Pisa, Italy), E. Svenungsson (Stockholm, Sweden)

**16:20-16:50 Coffee Break**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50</td>
<td><strong>LONGTERM OUTCOME</strong></td>
<td><strong>Chairs:</strong> E. Morand (Clayton, Australia), B. Pons-Estel (Rosario, Argentina)</td>
</tr>
<tr>
<td>16:50-17:10</td>
<td><strong>Mortality in SLE</strong></td>
<td>M. Tektonidou (Athens, Greece)</td>
</tr>
<tr>
<td>17:10-17:30</td>
<td><strong>SLE - when it doesn’t kill you what can it do longterm?</strong></td>
<td>D. Isenberg (London, UK)</td>
</tr>
<tr>
<td>17:30-17:50</td>
<td><strong>HrQoL</strong></td>
<td>S. Vordenbäumen (Düsseldorf, Germany)</td>
</tr>
<tr>
<td>17:50-18:00</td>
<td><strong>BETA2-MICROGLOBULIN (B2MG) PLASMA LEVELS ASSOCIATE WITH MARKERS OF ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)</strong></td>
<td>M.L.F. Hermansen, M. Faurschou, S. Jacobsen (Copenhagen, Denmark)</td>
</tr>
<tr>
<td>18:00-18:10</td>
<td><strong>HIGH GENETIC RISK SCORE IS ASSOCIATED WITH ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS</strong></td>
<td>S. Reid¹, A. Alexsson¹, M. Frodlund², E. Svenungsson³, J.K. Sandling¹, A. Jönsen⁴, C. Bengtsson⁵, I. Gunnarsson³, A.A. Bengtsson⁴, S. Rantapää-Dahlqvist⁶, A.C. Svänen¹, C. Sjöwall², L. Rönnblom¹, D. Leonard¹ (¹Uppsala, Sweden, ²Linköping, Sweden, ³Stockholm, Sweden, ⁴Lund, Sweden, ⁵Umeå, Sweden)</td>
</tr>
<tr>
<td>18:10-18:20</td>
<td><strong>A SIMPLE METHOD TO EVIDENCE SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS</strong></td>
<td>M. Parvu, S. Coman, M. Tilinca, S. Voidazan (TG. Mures, Romania)</td>
</tr>
<tr>
<td>18:20-18:30</td>
<td><strong>INCREASED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SLE WHO HAVE ASYMPTOMATIC PLAQUE ON VASCULAR ULTRASOUND - A FIVE-YEAR FOLLOW-UP STUDY</strong></td>
<td>J. Bakshi, D. Isenberg, A. Rahman (London, UK)</td>
</tr>
<tr>
<td>18:30-19:30</td>
<td><strong>SLEuro General Assembly</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

Room 3A

18:30-19:30 | SLEuro General Assembly

---

20 March, 16:50-18:30
Scientific Program

22 March, 16:50-18:30

**Room 3D**

**16:50-18:30**

**REPRODUCTION**

Chairs: N. Costedoat-Chalumeau (Paris, France), C. Specker (Essen, Germany)

16:50-17:10

**How to counsel SLE patients in childbearing age**

A. Tincani (Brescia, Italy)

17:10-17:30

**Are lupus pregnancies still “high risk”?**

R. Fischer-Betz (Düsseldorf, Germany)

17:30-17:50

**APS and pregnancy**

M. Khamashta (Dubai, UAE)

17:50-18:00

**VARIANT OF THE TNFSF13B GENE ENCODING FOR B-CELL ACTIVATING FACTOR CONFRS SUSCEPTIBILITY TO SLE, INCREASED SERUM BAFF CYOTOIKE AND AUTOANTIBODIES PRODUCTION**

M. Piga¹, M. Steri², V. Orrù², L. Idda², M. Pitzalis², F. Cucca², A. Mathieu¹

(¹Cagliari, Italy, ²Monserrato, Italy)

18:00-18:10

**TARGETED NEXT-GENERATION SEQUENCING SUGGESTS NOVEL RISK LOCI IN JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS**

J.K. Sandling¹, L. Hultin Rosenberg¹, F.H.G. Farias¹, A. Alexsson¹, D. Leonard¹, E. Murén¹, Å. Karlsson¹, A. Mathioudaki¹, D. Ericsson¹, G. Pielberg¹, J. Meadows¹, J. Nordin¹, J. Dahlqvist¹, M. Bianchi¹, S. Kozyrev¹, C. Bengtsson¹, A. Jönsen³, L. Padyukov⁴, M.L. Eloranta¹, C. Sjöwall⁵, I. Gunnarsson¹, E. Svenungsson⁴, S. Rantapää-Dahlqvist², A.A. Bengtsson³, A.C. Sylvåen¹, K. Lindblad-Toh¹, L. Rönnblom¹, The Dissect Consortium

(¹Uppsala, Sweden, ²Umeå, Sweden, ³Lund, Sweden, ⁴Stockholm, Sweden, ⁵Linköping, Sweden, ⁶Boston, USA)

18:10-18:20

**SLE COMPRISCE FOUR IMMUNE-PHENOTYPES, WHICH DIFFER REGARDING HLA-DRB1 AND CLINICAL ASSOCIATIONS**

L.M. Diaz Gallo¹, E. Lundström¹, V. Oke¹, K. Elvin¹, Y.L. Wu², J. Gustafsson¹, A. Jönsen³, D. Leonard⁴, A. Zickert¹, G. Nordmark⁴, A.A. Bengtsson³, J.K. Sandling⁴, L. Rönnblom⁴, I. Gunnarsson¹, C.Y. Yu², L. Padyukov¹, E. Svenungsson¹

(¹Stockholm, Sweden, Columbus, USA, ²Lund, Sweden, ³Uppsala, Sweden)

18:20-18:30

**NEXT GENERATION SEQUENCING IN HEMATOPOIETIC PROGENITORS OF MURINE SLE MODEL REVEALS ABERRANT REGULATION OF CEBP/A EXPRESSION**

M. Grigoriou¹, P. Verginis¹, C. Nikolaou², P. Pavlidis², E. Dermitzakis³, G. Bertsias², D. Boumpas¹, A. Banos¹

(¹Athens, Greece, ²Heraklion, Greece, ³Geneva, Switzerland)
### FRIDAY 23 MARCH 2018

#### Room 3A  
**08:00-09:00**  
**INDUSTRY - SPONSORED SYMPOSIUM** *(see page n. 70)*

**Room 3A**  
**09:00-10:30**  
**BIOMARKER & INDICES**  
Chairs: A. Doria (Padua, Italy), M. Tektonidou (Athens, Greece)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:20</td>
<td><strong>The genomic architecture of human SLE: clinical implication</strong></td>
<td>D. Boumpas (Athens, Greece)</td>
</tr>
<tr>
<td>09:20-09:40</td>
<td><strong>Association of serum IFN levels with lupus manifestations</strong></td>
<td>Z. Amoura (Paris, France)</td>
</tr>
<tr>
<td>09:40-10:00</td>
<td><strong>The molecular stratification of lupus</strong></td>
<td>M.E. Alarcón-Riquelme (Granada, Spain)</td>
</tr>
<tr>
<td>10:00-10:10</td>
<td><strong>CIRCULATING TYPE I, II AND III INTERFERONS (IFNS) ASSOCIATE WITH IFN-SCORES, BUT DEFINE DISTINCT SUBSETS OF ACTIVE SLE</strong></td>
<td>V. Oke¹, I. Gunnarsson¹, J.M. Dorschner², A. Zickert¹, T.B. Niewold³, E. Svenungsson¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(¹Stockholm, Sweden, ²Rochester, USA, ³New York, USA)</td>
</tr>
<tr>
<td>10:10-10:20</td>
<td><strong>GALECTIN-9 IS PRODUCED BY DENDRITIC CELLS AND SERUM LEVELS OUTPERFORM CXCL10 AS A BIOMARKER TO DETECT THE IFN SIGNATURE IN SLE AND APS</strong></td>
<td>L.L. Van Den Hoogen¹, J.A.G. Van Roon¹, J. Wienke¹, F. Van Wijk¹, R.D.E. Fritsch-Stork², T.R. Radstake¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(¹Utrecht, The Netherlands, ²Vienna, Austria)</td>
</tr>
<tr>
<td>10:20-10:30</td>
<td><strong>ANTI-CARBAMYLATED PROTEINS ANTIBODIES IN SLE PATIENTS WITH JOINT INVOLVEMENT: A POSSIBLE NEW BIOMARKER FOR EROSIVE DAMAGE</strong></td>
<td>F. Ceccarelli, C. Perricone, L. Massaro, T. Colasanti, E. Cipriano, M. Pendolino, F. Natalucci, G. Capalbo, R. Mancini, F.R. Spinelli, C. Alessandri, G. Valesini, F. Conti</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Rome, Italy)</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>09:00-10:30</td>
<td><strong>SUPPORTIVE THERAPIES</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: D. Boupas (Athens, Greece), D. D’Cruz (London, UK)</td>
<td></td>
</tr>
<tr>
<td>09:00-09:20</td>
<td>Update on infections in SLE patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J.M. Pego-Reigosa (Vigo, Spain)</td>
<td></td>
</tr>
<tr>
<td>09:20-09:40</td>
<td>HPV: the virus, the vaccines and SLE-similarities to EBV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Y. Shoenfeld (Tel-Hashomer, Israel - Saint Petersburg, Russia)</td>
<td></td>
</tr>
<tr>
<td>09:40-10:00</td>
<td>Smoking and SLE: a strong impact on disease prevalence, severity, and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>response to treatments</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Arnaud (Strasbourg, France)</td>
<td></td>
</tr>
<tr>
<td>10:00-10:10</td>
<td>LOW VITAMIN D IS ASSOCIATED WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Petri, W. Fu, D. Goldman</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Baltimore, USA)</td>
<td></td>
</tr>
<tr>
<td>10:10-10:20</td>
<td>BACTEREMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FROM RELESSER REGISTRY:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RISK FACTORS, CLINICAL AND MICROBIOLOGICAL CHARACTERISTICS AND OUTCOMES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Lois Iglesias¹, J.M. Pego-Reigosa², F.J. López-Longo³, M. Galindo³,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>V. Delcampo-Pérez², J. Torres-Cisneros⁴, E. Uriarte⁵, P. Vela⁶, E. Tomero⁶,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Erausquin⁷, A. Naranjo⁷, J.M. Calvo-Alén⁸, A. Fdez-Nebro⁹, A. Rúa-Figueroa¹⁰,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(*Coruña, Spain, ²Vigo, Spain, ³Madrid, Spain, ⁴Córdoba, Spain, ⁵San Sebastian,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>⁶Alicante, Spain, ⁷Gran Canaria, Spain, ⁸Alava, Spain, ⁹Malaga, Spain)</td>
<td></td>
</tr>
<tr>
<td>10:20-10:30</td>
<td>SERIOUS INFECTION RATES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SWEDISH POPULATION-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BASED ASSESSMENT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Simard¹², M. Rossides¹, E. Arkema¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(*Stockholm, Sweden, ²Stanford, USA)</td>
<td></td>
</tr>
</tbody>
</table>

**Coffee Break**
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50-12:30</td>
<td>MAINTAINANCE THERAPY</td>
<td>Chairs: Z. Amoura (Paris, France), D. Isenberg (London, UK)</td>
</tr>
<tr>
<td>10:50-11:10</td>
<td>Long term effects of reduced-dose glucocorticoid schedules in patients with SLE</td>
<td>G. Ruiz-Irastorza (Barakaldo, Spain)</td>
</tr>
<tr>
<td>11:10-11:30</td>
<td>How to improve adherence to treatment in SLE</td>
<td>N. Costedoat-Chalumeau (Paris, France)</td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>Calcineurin inhibition in lupus nephritis, an old story or a new dawn?</td>
<td>D. Jayne (Cambridge, UK)</td>
</tr>
<tr>
<td>11:50-12:00</td>
<td>A POPULATION-BASED STUDY ON MORTALITY AND THE INFLUENCE OF MEDICATION USE IN 4356 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND 21845 MATCHED CONTROLS FROM THE UNITED KINGDOM</td>
<td>I.E. Bultink¹, F. De Vries²³, R. Van Vollenhoven¹, A. Lalmohamed² (¹Amsterdam, The Netherlands, ²Utrecht, The Netherlands, ³Maastricht, The Netherlands)</td>
</tr>
<tr>
<td>12:00-12:10</td>
<td>THE 3RS STRATEGY ONE YEAR LATER: STILL REACHING THE GOAL</td>
<td>A.V. Taulaigo, A. Lladó, M. Vicente, M.F. Moraes-Fontes (Lisbon, Portugal)</td>
</tr>
<tr>
<td>12:10-12:20</td>
<td>SCREENING IN PATIENTS AT HIGH RISK OF HYDROXYCHLOROQUINE RETINAL TOXICITY</td>
<td>A. Dias Santos, A.V. Taulaigo, E. Patarata, S. Guerreiro Castro, M.F. Moraes-Fontes (Lisbon, Portugal)</td>
</tr>
<tr>
<td>12:20-12:30</td>
<td>EXPLORER STUDY: RITUXIMAB USE IN SYSTEMIC LUPUS ERYTHEMATOSUS, A NEW LOOK ON OLD DATA</td>
<td>M. Scherlinger, C. Carcaud, T. Barnetche, P. Dufau, L. Couzy, E. Lazaro, C. Richez (Bordeaux, France)</td>
</tr>
</tbody>
</table>
### Scientific Program

**Room 3D**

**10:50-12:30**

**IMMUNOPATHOGENESIS II**

Chairs: C. Chizzolini (Geneva, Switzerland), R. Voll (Freiburg, Germany)

- **10:50-11:10**
  - Distinctive microparticle subsets in patients with SLE
  - S. Jacobsen (Copenhagen, Denmark)

- **11:10-11:30**
  - Immunometabolism in systemic lupus erythematosus
  - L. Morel (Gainesville, USA)

- **11:30-11:50**
  - Immunological factors contributing to development of cardiovascular disease in patients with SLE
  - A. Rahman (London, UK)

- **11:50-12:00**
  - Antibodies to myelin oligodendrocyte glycoprotein in patients with SLE are associated with central nervous system involvement: An unbiased pilot study of the Swiss SLE cohort study (SSCS)
  - A. Pröbstel¹, M. Thanei¹, B. Erni¹, A.C. Lecourt¹, L. Branco¹, R. André², K.F. Koenig¹, U. Huynh-Do³, C. Ribi⁴, C. Chizzolini², L. Kappos¹, M. Trendelenburg¹, T. Derfuss¹
  
  (¹Basel, Switzerland, ²Geneva, Switzerland, ³Bern, Switzerland, ⁴Lausanne, Switzerland)

- **12:00-12:10**
  - Antiphospholipid antibodies differentially regulate the expression & activity of the lysosomal proteases with effects upon monocyte autophagy
  - V. Ripoll, A. Khawaja, I. Giles, A. Rahman
  
  (London, UK)

- **12:10-12:20**
  - Inhibition of EIF4A translation initiation ameliorates lupus manifestations
  - M. Morell, G. Gómez-Hernández, N. Varela, M.E. Alarcón-Riquelme
  
  (Granada, Spain)

- **12:20-12:30**
  - Novel alpha-1-antitrypsin fragment as potential treatment of systemic lupus erythematosus
  - U. Wormser, B. Brodsky, Y. Finkelstein, E. Shapira, E. Proscura
  
  (Jerusalem, Israel)

**12:30-14:00**

Lunch and E-Poster Discussion
**Scientific Program**

*Room 3A*

**14:00-15:00**  
**INDUSTRY - SPONSORED SYMPOSIUM** *(see page n. 71)*

*Poster Area*

**15:15-16:15**  
**FISHBOWL AND OPEN CHAIR - DISCUSSION ROUNDS** *(rules at page 56)*

**Fishbowl 1**  
Measuring lupus disease activity in daily clinical practice: challenges and unmet needs *(based on cases)*  
Moderator: A. Schwarting (Mainz, Germany)

*Discussants:*
J. Andersen (Knebel, Denmark), F. Basta (Rome, Italy)  
L.P. Sousa Ines (Coimbra, Portugal), M. Tektonidou (Athens, Greece)

**Fishbowl 2**  
Who takes care of lupus patients?  
Moderator: C. Specker (Essen, Germany)

*Discussants:*
N. Costedoat-Chalumeau (Paris, France), D. D'Cruz (London, UK)  
Y. Norton (Coseley, UK), A.V. Taulaigo (Oeiras, Portugal)

**Fishbowl 3**  
B cell depleting treatment in lupus  
Moderator: F. Hiepe (Berlin, Germany)

*Discussants:*
C. Chizzolini (Geneva, Switzerland), T. McDonnell (Hitchin, UK),  
A. Rahman (London, UK), Y.K.O. Teng (Leiden, The Netherlands)
Fishbowl 4  Fatigue in lupus: feature of the disease or conditioning by patient ‘education’?
Moderator: T. Morel (Leuven, Belgium)
Discussants:
D. Boumpas (Athens, Greece), B. Van Leeuw (Ottignies, Belgium)
C. Vasconcelos (Porto, Portugal), C. Wincup (London, UK)

Fishbowl 5  How to improve lupus outcome?
Moderator: R. Fischer-Betz (Düsseldorf, Germany)
Discussants:
A. Doria (Padua, Italy), C. Düsing (Düsseldorf, Germany)
K. Lerstrøm (Farum, Denmark), J. Smolen (Vienna, Austria)

16:20-16:50  Coffee Break
Scientific Program

**Room 3A**  
**16:50-18:40** NEW THERAPEUTIC CANDIDATES  
Chairs: M. Mosca (Pisa, Italy), J.M. Pego-Reigosa (Vigo, Spain)

16:50-17:10 Novel therapies for SLE  
R. Furie (New York, USA)

17:10-17:30 B cell directed therapies in SLE  
R. Van Vollenhoven (Amsterdam, The Netherlands)

17:30-17:50 Biologic therapy for SLE beyond rituximab, belimumab and interferon alpha blockade—encouraging signs!  
D. Isenberg (London, UK)

17:50-18:00 REDUCTION OF SYSTEMIC LUPUS FLARES BY ATACICEPT IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE IIIB STUDY (ADDRESS II) AND ITS EXTENSION STUDY  
D.J. Wallace¹, D. Isenberg², A. Kao³, C. Vazquez-Mateo³, P. Fleuranceau-Morel³, P. Chang⁴, J.T. Merril⁴  
(¹Los Angeles, USA, ²London, UK, ³Billerica, USA, ⁴Oklahoma City, USA)

18:00-18:10 SRI RESPONSE, ATTAINMENT OF LOW DISEASE ACTIVITY AND SAFETY IN PATIENTS WITH SYSTEMIC LUPUS TREATED WITH ATACICEPT IN A PHASE IIIB STUDY (ADDRESS II)  
J.T. Merril¹, E. Morand², D.J. Wallace³, A. Kao⁴, C. Vazquez-Mateo⁴, P. Chang⁴, P. Fleuranceau-Morel⁴, D.A. Isenberg⁵  
(¹Oklahoma City, USA, ²Melbourne, Australia, ³Los Angeles, USA, ⁴Billerica, USA, ⁵London, UK)

18:10-18:20 BASELINE SERUM LEVELS OF BAFF OR APRIL ARE INDEPENDENT PREDICTORS OF SLEDAI RESPONSE AFTER 12 MONTHS OF TREATMENT WITH BELIMUMAB IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS  
S. Piantoni¹, L. Andreoli¹, T. Lowin², R. Kumar¹, F. Regola¹, P. Airò¹, F. Franceschini¹, A. Tincani¹, G. Pongratz²  
(¹Brescia, Italy, ²Düsseldorf, Germany)

18:20-18:30 ADMINISTRATION OF SERPINB3 DELAYS GLOMERULONEPHRITIS AND ATTENUATES THE LUPUS-LIKE DISEASE IN LUPUS MURINE MODELS BY AN IMMUNOMODULATORY EFFECT  
(Padua, Italy)

18:30-18:40 EFFICACY AND SAFETY OF USTEKINUMAB, AN INTERLEUKIN 12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED STUDY  
R. Van Vollenhoven¹, B.H. Hahn², G.C. Tsokos³, C. Wagner⁴, P. Lipsky⁵, B. Hsu⁴, M. Chevrier⁴, R. Gordon⁴, M. Triebel⁶, S. Rose⁴  
(¹Amsterdam, The Netherlands, ²Los Angeles, USA, ³Boston, USA, ⁴Spring House, USA, ⁵Charlottesville, USA, ⁶Leiden, The Netherlands)

---

**Room 3A**  
**18:40-19:00** CLOSING CEREMONY AND POSTER AWARDS
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:50-17:10</td>
<td><strong>Patient vs. Doctor’s reported measures of disease activity</strong></td>
<td>E. Svenungsson (Stockholm, Sweden)</td>
</tr>
<tr>
<td>17:10-17:30</td>
<td><strong>Assessment and management of fatigue in SLE</strong></td>
<td>D. D'Cruz (London, UK)</td>
</tr>
<tr>
<td>17:30-17:50</td>
<td><strong>LuLa: PRO cohort</strong></td>
<td>G. Chehab (Düsseldorf, Germany)</td>
</tr>
<tr>
<td>18:00-18:10</td>
<td><strong>THE DIAGNOSTIC PHASE OF LUPUS – BEING IN A STANDSTILL-OF-LIFE</strong></td>
<td>J. Lisander Larsen¹, E.O.C. Hall², S. Jacobsen¹, R. Birkelund³ (¹Copenhagen, Denmark, ²Aarhus, Denmark, ³Vejle, Denmark)</td>
</tr>
<tr>
<td>18:20-18:30</td>
<td><strong>IDENTIFYING THE LINKS BETWEEN FUNCTIONAL IRON DEFICIENCY AND FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS</strong></td>
<td>C. Wincup¹, C. Parnell¹, S. Cleanthous¹, S. O'neill², M. Nguyen², T. Richards¹, A. Rahman¹ (¹London, UK, ²Sydney, Australia)</td>
</tr>
</tbody>
</table>
Poster Sessions

E-POSTER DISCUSSION (Thursday 22 March, 12:00 - 13:30)

Poster Area, E-Poster Station 1
POSTER SESSION 1: AUTOANTIBODIES, BIOMARKERS AND IMAGING (1)
Chairs: F. Hiepe (Berlin, Germany), R. Voll (Freiburg, Germany)

PS1:1 HIGH TYPE I INTERFERON ACTIVITY IS ASSOCIATED WITH ACTIVE CLASS 3/4 LUPUS NEPHRITIS IN EUROPEAN-AMERICAN LUPUS PATIENTS INDEPENDENT OF ANTI-DSDNA ANTIBODIES
T. Iwamoto1, J.M. Dorschner2, M.A. Jensen1, D. Vsetecka2, S. Amin2, A. Makol2, F.C. Ernste2, T. Osborn2, K.G. Moder2, V. Chowdhary2, T.B. Niewold1
(1New York, USA, 2Rochester, USA)

PS1:2 DEVELOPMENT OF A MULTIMARKER MODEL FOR THE DETECTION OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON NEW AND TRADITIONAL AUTOANTIBODIES
P. Budde1, H.D. Zucht1, T. Witte2, M. Schneider3, P. Schulz-Knappe1
(1Dortmund, Germany, 2Hannover, Germany, 3Düsseldorf, Germany)

PS1:3 ANALYSIS OF C9ORF72 EXPANSIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS: PRELIMINARY DATA
M. Fredi, G. Biasiotto, I. Cavazzana, M. Filosto, A. Padovani, F. Franceschini, I. Zanella
(Brescia, Italy)

PS1:4 SEARCHING BIOMARKERS IN LUPUS NEPHRITIS BY PROTEOMICS
(Bilbao, Spain)

PS1:5 INTERFERON SIGNATURE IS INCREASED IN INCOMPLETE SLE AND CORRELATES WITH CMX AND IP-10 LEVELS
W. Lambers, J. Westra, B. Doornbos, M.F. Jonkman, H. Bootsma, K. de Leeuw
(Groningen, The Netherlands)

PS1:6 DIFFERENTIAL DIAGNOSIS OF AUTOIMMUNE DISEASES, OUTLIER DETECTION PLUS SUBGROUPING IN CLINICAL TRIALS BY HIGH CONTENT AUTOANTIBODY PROFILING
P. Schulz-Knappe, P. Budde, H.D. Zucht
(Dortmund, Germany)

PS1:7 ANTINUCLEAR ANTIBODY(ANA) AND ANTINEUTROPHIL CYTOPLASMIC ANTIBODY TESTING IN A TERTIARY HEALTH ENTRE IN SHERBROOKE: AN ASSESSMENT OF THE ADHERENCE TO THE GUIDELINES AND THE IMPACTS ON THE DIAGNOSIS AND HEALTH CARE SYSTEM
M. Parfenova
(Sherbrooke, Canada)
PS1:8 ANTI-RO FALSE-NEGATIVES DETECTION THROUGH ANTI-RO52 KDA AND ANTI-RO60 KDA ANALYSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

PS1:9 B CELL SUBPOPULATIONS IN LUPUS NEPHRITIS PATIENTS: CORRELATIONS WITH DISEASE ONSET AND OUTCOMES
V. Varriano, L. Petricca, S. Costanzi, M. Gigante, A. Paglioniico, G. Tanti, G. Vischini, G. Ferraccioli, E. Gremese (Rome, Italy)

PS1:10 EFFECTS OF BELIMUMAB TREATMENT ON B CELL HYPERACTIVITY AND TYPE-I INTERFERON EXPRESSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
J. Martin¹, Q. Cheng¹, S.A. Laurent², F.S. Thaler², E. Meinl², A. Radbruch¹, F. Hiepe¹ (¹Berlin, Germany, ²Munich, Germany)

PS1:11 THE INTERFERON BIOMARKER SIGLEC1 REFLECTS DISEASE ACTIVITY IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
V.S. Sae Lim, J. Klotsche, M. Heinrich, J. Thumfart, R. Biesen, C. Meisel, N. Unterwalder, T. Kallinich (Berlin, Germany)

PS1:13 SYSTEMIC LUPUS ERYTHEMATOSUS WITH POSITIVE ANTICENTROMERE ANTIBODIES - A DIFFERENT CLINICAL SUBGROUP?
J. Caetano¹, C. Favas¹, M. Amaral¹², S. Oliveira¹, J.D. Alves¹² (¹Amadora, Portugal, ²Lisbon, Portugal)

PS1:14 TRPV1 RECEPTOR ACTIVITY IN LUPUS
M. Sahebari, S.Z. Mirfeizi, J. Salimi (Mashhad, Iran)

PS1:15 EXPRESSION OF ADHESION MOLECULES CD44V3 AND CD44V6 ON T CELLS IN SLE PATIENTS: CORRELATION WITH CLINICAL PHENOTYPE AND DISEASE ACTIVITY
L. Novelli, C. Barbati, F. Ceccarelli, C. Perricone, F.R. Spinelli, C. Alessandri, G. Valesini, R. Perricone, F. Conti (Rome, Italy)

PS1:16 THE PRESENCE OF AUTOANTIBODIES TO MULTIPLE KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS IS ASSOCIATED WITH NEPHRITIS IN SLE PATIENTS
N. Hagberg, D. Leonard, G. Nordmark, L. Rönnblom (Uppsala, Sweden)
PS1:17 LUPUS NEPHRITIS: SEVERELY REDUCED URINARY DNASE I LEVELS REFLECT LOSS OF RENAL DNASE I, DISEASE PROGRESSION AND MAY REDUCE THE NEED FOR RENAL BIOPSIES
H.L. Pedersen¹, K.D. Horvei¹, D. Thiyagarajan¹, G.E. Norby², N. Seredkina¹, G. Moroni³, H. Holdaas³, E.H. Strøm², P.L. Meroni², O.P. Rekvig¹
(¹Tromsø, Norway, ²Oslo, Norway, ³Milan, Italy)

PS1:18 ECHOCARDIOGRAPHY FOR THE ASSESSMENT OF CARDIOVASCULAR BURDEN IN LUPUS: A SINGLE CENTER COHORT STUDY
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, C. Iordache, R. Chirieac, F. Mitu
(Iași, Romania)

PS1:19 BIOLOGICAL DMARDS-INDUCED LUPUS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SINGLE CENTRE EXPERIENCE
C. Ancuta, C. Pomirleanu, R. Paiu, C. Iordache, E. Ancuta, R. Chirieac
(Iași, Romania)

PS1:20 MINING FOR COMMON REACTIVITY PATTERNS OF HUMAN AUTOANTIBODIES AGAINST ENDOGENOUS PROTEIN TARGETS USING CLUSTERED AUTOANTIBODY REACTIVITIES
(Dortmund, Germany)

PS1:21 URINARY MARKERS OF INFLAMMATION IN LUPUS NEPHRITIS PATIENTS
J. Kosalka, B. Jakiela, J. Musial
(Krakow, Poland)

PS1:22 USE OF INTERFERON ALPHA AND INTERLEUKIN-10 AS CLINICAL ACTIVITY BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS
(Valencia, Spain)
PS2:23 ANTI-C1Q ANTIBODIES IN TURKISH SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
S. Tekeoglu, D. Temiz Karadag, O. Ozdemir Isik, A. Yazici, A. Cefle
(Kocaeli, Turkey)

PS2:24 PLASMATIC AND URINARY ENDOTHELIAL MICROPARTICLES ARE INCREASED IN PATIENTS WITH LUPUS NEPHRITIS
F. Miranda, C. Barbati, S. Truglia, F.R. Spinelli, F. Ceccarelli, C. Alessandri, G. Valesini, F. Conti
(Rome, Italy)

PS2:25 ANALYSIS OF THE POLYAMINE METABOLOME IN THE PLASMA OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND FEVER
C. Suh, W. Baek, S. Lee, H. Kim, J. Jung
(Suwon, South Korea)

PS2:26 SLE PATIENTS WITH SECONDARY SJÖGREN´S SYNDROME ARE CHARACTERIZED BY TYPICAL AUTOANTIBODIES AND A PRO-INFLAMMATORY STATE
M. Kvarnström¹, G. Ruacho², J. Gustafsson¹, A. Zickert¹, V. Oke³, J. Rönnelid², K. Elvin¹, I. Gunnarsson¹, E. Svenungsson¹
(¹Stockholm, Sweden, ²Uppsala, Sweden)

PS2:27 ANTIBODIES TO CARBAMYLATED VIMENTIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH RENAL INVOLVEMENT
(Rome, Italy)

PS2:28 AUTOANTIBODY PROFILING IN PROSTVAC AND IPILIMUMAB TREATED PROSTATE CANCER PATIENTS REVEALS POTENTIAL BIOMARKERS OF IMMUNE-RELATED ADVERSE EVENTS
P. Budde¹, J. Marte¹, H.D. Zucht¹, S. Bhandari¹, M. Tuschen¹, P. Schulz-Knappe¹, J. Gulley², C. Heery³, R. Madan², J. Schlom²
(¹Dortmund, Germany, ²Bethesda, USA, ³Morrisville, USA)

PS2:29 THE INCIDENCE AND POSSIBLE RISK FACTORS OF LOW BONE MINERAL DENSITY IN KOREAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
C. Suh, J. Jung, W. Baek, S. Lee
(Suwon, South Korea)
PS2:30 SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH POSITIVE AUTOANTIBODIES WITH REMISSION OR LOW ACTIVITY EXHIBIT BOTH LOWER INTERFERON ALPHA AND INTERLEUKIN-10 LEVELS
(Valencia, Spain)

PS2:31 AGE AND AN AUTOANTIBODY ALGORITHM HELPS DISTINGUISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM THOSE WITH SJÖGREN’S SYNDROME
K.G. Moder, C.S. Crowson, M.R. Snyder
(Rochester, USA)

PS2:32 CD64, FC GAMMA R I EXPRESSION LEVELS ON MONOCYTE (MCD64) AS A POTENTIAL BIOMARKER FOR NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS (NPSLE)
(Kawachinagano, Japan)

PS2:33 MICROPARTICLES FROM SLE PATIENTS ARE A SOURCE OF INTERFERON-ALPHA
F. Miranda, C. Barbati, F.R. Spinelli, F. Ceccarelli, S. Truglia, C. Alessandri, G. Valesini, F. Conti
(Rome, Italy)

PS2:34 THE EFFECT OF AUTO-ANTIBODY POSITIVITY ON DAMAGE AND DEATH IN A LARGE COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 40-YEAR FOLLOW-UP STUDY
B.S. Bernstein, C. Wincup, T. McDonnell, B. Tejera Segura, A. Rahman
(London, UK)

PS2:35 CLINICAL, BIOLOGICAL AND IMMUNOLOGICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A TUNISIAN COHORT
M. Kechida, R. Mesfar, R. Klii, S. Hammami, I. Khochtali
(Monastir, Tunisia)

PS2:36 PREVALENCE OF THYROID DISEASES IN SLE PATIENTS AMONG SAUDI POPULATION
I. Al-Homood, R. AlKhathami, M. Al Yousef, S. Al Johani
(Riyadh, Saudi Arabia)
**PS2:37** ANTI-SMITH ANTIBODIES INFLUENCE ON CLINICAL, BIOLOGICAL AND IMMUNOLOGICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN TUNISIAN PATIENTS

**PS2:38** COMPARATIVE TISSUE TRANSCRIPTOME ANALYSIS BY NEXT-GENERATION SEQUENCING REVEALS NOVEL PATHWAYS THAT CHARACTERIZE GENETIC SUSCEPTIBILITY AND DEVELOPMENTAL BIOLOGY IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
E. Frangou¹,², M. Grigoriy¹, A. Banos¹, G. Bertsiás³, E. Dermitzakis¹,⁴, D. Boumpas¹,² (¹Athens, Greece, ²Nicosia, Cyprus, ³Heraklion, Greece, ⁴Geneva, Switzerland)

**PS2:39** GENETIC AND ENVIRONMENTAL RISK FACTORS FOR SYSTEMIC LUPUS ERYTHEMATOSUS - A NATIONWIDE POPULATION STUDY
H. Leffers, S. Jacobsen, H. Ullum, T. Lange (Copenhagen, Denmark)

**PS2:40** ASSOCIATION OF PEPTIDYLARGININE DEIMINASE (PADI)-4 POLYMORPHISMS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS
L. Massarenti, C. Enevold, D. Damgaard, N. Ødum, C.H. Nielsen, S. Jacobsen (Copenhagen, Denmark)

**PS2:41** MICRORNA-155 AND DISEASE ACTIVITY IN SLE PATIENTS
R. Shumnalieva¹, D. Kachakova², V. Shoumnalieva-Ivanova¹, P. Miteva¹, D. Monova¹, R. Kaneva¹, S. Monovic¹, V. Popova² (¹Sofia, Bulgaria, ²Plovdiv, Bulgaria)

**PS2:42** UNMETHYLATED CPG-RICH DNA FRAGMENTS ARE ASSOCIATED WITH THE PRESENCE OF LUPUS NEPHRITIS AND INFLUENCE TLR9-MEDIATED RENAL RESPONSE
P. Korsten, D. Tampe, G.A. Müller, M. Zeisberg, B. Tampe (Göttingen, Germany)

**PS2:43** IS LUPUS MORE PREVALENT IN WORLD’S MOST STRESSED COUNTRIES?
A. Almathkouri, D. Pyne, A. Pakozdi, M. Lewis, A. Cove-Smith, R. Rajakariar (London, UK)

**PS2:44** ROLE OF ANTI-DFS70 ANTIBODIES IN THE SEROLOGICAL DIAGNOSTICS OF SLE
N. Röber¹, M. Achleitner¹, M. Aringer¹, S. Rudolph², L. Unger², A. Gräßler³, K. Lüthke¹, M. Mahler³, K. Conrad¹ (¹Dresden, Germany, ²Chemnitz, Germany, ³Dresden-Friedrichstadt, Germany, ⁴Pirna, Germany, ⁵San Diego, USA)
PS3:45 SPATIAL-TIME CLUSTER ANALYSIS OF SLE DISEASE ACTIVITY
G. Stojan, F. Curriero, A. Kvit, M. Petri
(Baltimore, USA)

PS3:46 RELATIONSHIP BETWEEN DAMAGE CLUSTERING AND MORTALITY IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: CLUSTER ANALYSES IN A LARGE COHORT FROM THE SPANISH SOCIETY OF RHEUMATOLOGY, LUPUS REGISTRY
V. Torrente-Segarra¹, T.C. Salman-Monte², I. Rúa-Figueroa³, J.M. Calvo-Alén⁴, F.J. López-Longo⁵, M. Galindo⁶, A. Olivé⁷, J.M. Pego-Reigosa⁷
(¹Llobregat, Spain, ²Barcelona, Spain, ³Las Palmas De Gran Canaria, Spain, ⁴Bilbao, Spain, ⁵Madrid, Spain, ⁶Badalona, Spain, ⁷Vigo, Spain)

PS3:47 MULTI-YEAR ANALYSIS OF PREVALENCE/OUTCOMES OF PULMONARY EMBOLISM IN SYSTEMIC LUPUS ERYTHEMATOSUS DISCHARGES FROM NATIONWIDE INPATIENT SAMPLE DATABASE & COMPARISON TO NATIONAL HOSPITAL DISCHARGE SURVEY
V. Majithia, T. Nasir, S. Lirette, S. Kishore
(Jackson, USA)

PS3:48 THE INCIDENCE OF CARDIOVASCULAR EVENTS IN ITALIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS LOWER THAN IN NORTH EUROPEAN AND AMERICAN COHORTS: IMPLICATION OF DISEASE-ASSOCIATED AND TRADITIONAL RISKS
S. Fasano¹, D.P. Margiotta², R. Gualtierotti³, A. Corrado⁴, O. Berardicurti⁵, L. Pierro¹, A. Riccardi¹, R. Giacomelli⁵, F.P. Cantatore⁴, P.L. Meroni³, A. Afetra², G. Valentini¹
(¹Naples, Italy, ²Rome, Italy, ³Milan, Italy, ⁴Foggia, Italy, ⁵L’Aquila, Italy)

PS3:49 EVALUATION OF CAPILLAROSCOPIC PATTERN IN SLE PATIENTS WITH AND WITHOUT RAYNAUD SYMPTOM
G. Nagy, L. Czirják, G. Kumánovics
(Pécs, Hungary)

PS3:50 INCIDENCE, DISEASE SEVERITY AND OUTCOME OF LUPUS NEPHRITIS. RESULTS FROM AN INCEPTION COHORT OF HISPANIC SLE PATIENTS.
J.V. Medina-Gomez, M.C. Ocampo-Torres, P. Lara-Reyes, Z. Garcia-Sanabria, J. Romero-Diaz
(Mexico City, Mexico)

PS3:51 MULTIMORBIDITY BURDEN IN SLE: PRELIMINARY DATA FROM THE COMMUNITY-BASED LUPUS REGISTRY OF CRETE
I. Gergianaki¹, C. Adamichou¹, G. Spyrou¹, A. Kountouri¹, P. Sidiropoulos¹, D. Boumpas¹², G. Bertsias¹
(¹Iraklio, Greece, ²Athens, Greece)
PS3:52 INCIDENCE AND CLINICAL FEATURES OF NEUROPSYCHIATRIC LUPUS IN KOREA: A PROSPECTIVE SINGLE-CENTER STUDY
G.Y. Ahn¹, D. Kim¹, S.Y. Won¹, S.T. Song², H.J. Jung³, I.W. Son¹, S. Lee⁴, Y.B. Joo⁵, S.C. Bae¹
(¹Seoul, South Korea, ²Cheongju, South Korea, ³Daegu, South Korea, ⁴Busan, South Korea, ⁵Suwon, South Korea)

PS3:53 CROSS-CULTURAL VALIDATION OF THE DISEASE SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE LUPUSQOL IN THE PHILIPPINES
A.J. Miranda, E.G. Penserga
(Manila, Philippines)

PS3:54 CHARACTERISTIC FEATURES OF HEMATOLOGICAL INVOLVEMENT AND ITS EFFECT ON DAMAGE ACCRUAL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOUSUS: PRELIMINARY RESULTS FROM A MULTICENTER EUROPEAN COHORT
S. Yavuz¹, D. Cansu², F. Crisafulli³, A. Antunes⁴, D. Nikolopoulos⁵, K. Tascilar¹, C. Korkmaz², L. Andreoli³, M.F. Moraes-Fontes⁴, A. Tincani³, G. Bertsias⁵
(¹Istanbul, Turkey, ²Eskisehir, Turkey, ³Brescia, Italy, ⁴Lisbon, Portugal, ⁵Athens, Greece)

PS3:57 IMPACT OF LUPUSNEPHRITIS ON MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. A POPULATION BASED COHORT FROM NORWAY.
S.E.R. Moe, Ø. Molberg, E.H. Strøm, K. Lerang
(Oslo, Norway)

PS3:58 LIPID PROFILE CHARACTERIZATION IN PATIENTS WITH JUVENILE SLE WITH AND WITHOUT LUPUS NEPHRITIS – EXPERIENCE OF A PORTUGUESE CENTER
A. Águeda¹², M. Guerra², I. Jorge², R. Ferreira², M. Rodrigues², I. Brito²
(¹Aveiro, Portugal, ²Porto, Portugal)

PS3:59 IS THERE A DIFFERENCE BETWEEN LIPID PROFILE BEFORE AND AFTER LUPUS NEPHRITIS TREATMENT IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS?
I. Santos Jorge¹, M. Guerra², A. Águeda³, R. Ferreira¹, M. Rodrigues¹, I. Brito¹
(¹Porto, Portugal, ²Vila Nova De Gaia, Portugal, ³Aveiro, Portugal)

PS3:60 INCIDENCE OF VASCULITIS IN HOSPITALIZED LUPUS PATIENTS
S.Z. Mirfeizi¹, Z. Shariati Sarabi¹, E. Aatabati², R. Ranjbar¹, M. Sahebari¹, K. Hashemzadeh¹
(¹Mashhad, Iran, ²Birjand, Iran)

PS3:62 IS THERE A RELATIONSHIP BETWEEN VITAMIN D AND COMPLEMENT IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS?
M. Guerra¹, A. Águeda², I. Jorge³, R. Ferreira³, M. Rodrigues³, I. Brito³
(¹Vila Nova de Gaia, Portugal, ²Aveiro, Portugal, ³Porto, Portugal)
PS3:63 NOT ALL PATIENTS WITH LUPUS ARE SIMILAR
(Oviedo Asturias, Spain)

PS3:64 CLINICAL FEATURES OF ANTI-RNP POSITIVE PATIENTS IN KOREA
S.H. Chang, S.W. Lee
(Cheonan, South Korea)

PS3:65 VITAMIN D DEFICIENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATIONSHIP WITH DISEASE ACTIVITY
L. Athanassiou¹, I. Kostoglou-Athanassiou¹, C. Katsavouni², A. Tzanavari², A. Koteli², C. Mavragani¹, M. Koutsilieris¹, P. Athanassiou¹
(¹Athens, Greece, ²Thessaloniki, Greece)

Poster Area, E-Poster Station 4
POSTER SESSION 4: APS, FAMILY PLANNING, FERTILITY, PREGNANCY AND NEONATAL CARE
Chairs: N. Costedoat-Chalumeau (Paris, France), A. Tincani (Brescia, Italy)

PS4:66 PROLONGED EXPOSURE TO ANTIPHOSPHOLIPID ANTIBODIES IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
C. Cho¹, Y. Park², I. Baek¹, W. Kim¹
(¹Seoul, South Korea, ²Suwon, South Korea)

PS4:67 LOSING ANTIPHOSPHOLIPID ANTIBODY POSITIVITY POST THROMBOSIS IN SECONDARY ANTIPHOSPHOLIPID SYNDROME
M. Khawaja, L. Magder, M. Petri
(Baltimore, USA)

PS4:68 CAROTID AND FEMORAL ATHEROSCLEROSIS IN ANTIPHOSPHOLIPID SYNDROME: EQUIVALENT RISK WITH DIABETES MELLITUS IN A CASE-CONTROL STUDY
M. Tektonidou, E. Kravvariti, G. Konstantonis, N. Tentolouris, P.P. Sfikakis
(Athens, Greece)
PS4:69 EPIDEMIOLOGY OF VASCULAR PRIMARY ANTIPHOSPHOLIPID ANTIBODIES SYNDROME
(Brescia, Italy)

PS4:70 ANTI-PHOSPHATIDYLSERINE / PROTHROMBIN ANTIBODIES AND CARDIOVASCULAR RISK IN A SLE COHORT OF PATIENTS
V. Canti, G.A. Ramirez, E. Bozzolo, S. Del Rosso, R. Erra, A. Manfredi, P. Rovere-Querini
(Milan, Italy)

PS4:71 IGA ANTIPHOSPHOLIPID ANTIBODIES IN SWEDISH CASES WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATIONS WITH DISEASE PHENOTYPES, VASCULAR EVENTS AND DAMAGE ACCRUAL
M. Frodlund1, A. Vikerfors2, G. Grosso2, T. Skogh1, J. Wetterö1, K. Elvin2, I. Gunnarsson2, A. Kastbom1, Ö. Dahlström1, J. Rönnelid3, E. Svenungsson2, C. Sjöwall1
(1Linköping, Sweden, 2Stockholm, Sweden, 3Uppsala, Sweden)

PS4:72 ANTIPHOSPHOLIPID ANTIBODIES AND AUTOIMMUNE HEMOLITIC ANEMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-CONTROL STUDY
F. Crisafulli, L. Andreoli, F. Franceschini, M. Frassi, M. Fredi, C. Nalli, A. Tincani
(Brescia, Italy)

PS4:73 EFFECT OF HYDROXYCHLOROQUINE AND PREDNISONE TREATMENT ON ANTIPHOSPHOLIPID TITERS IN SLE
M. Avci1, L. Magder2, M. Petri2
(1Istanbul, Turkey, 2Baltimore, USA)

PS4:74 PRIMARY ANTIPHOSPHOLIPID SYNDROME PRESENTING WITH PURPURA FULMINANS - THERAPEUTIC RESPONSE TO GLUCOCORTICOIDS, ANTICOAGULATION AND PLASMA EXCHANGE
M. Plüß, M. Zeisberg, G.A. Müller, P. Korsten
(Göttingen, Germany)

PS4:75 BLEEDING IN A YOUNG GIRL WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODIES
(Chandigarh, India)

PS4:76 THE CHALLENGE OF CENTRAL NERVOUS SYSTEM SMALL VESSEL DISEASE IN AUTOIMMUNITY: A CASE REPORT
L. Duarte, M.P. Anselmo, C. Mendes, C. Mota, J.M. Lopes, J. Meneses, R. Victorino
(Lisbon, Portugal)
PS4:77 TWO CASES OF FATAL CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME
L. Castelnovo1, A. Laria2, A. Lurati2, A. Tamburello1, P. Faggioli1, A. Mazzone1
(1Legnano, Italy, 2Magenta, Italy)

PS4:78 WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS MORE OFTEN ACHIEVE
PREGNANCY, AND HAVE A SHORTER TIME TO PREGNANCY COMPARED TO WOMEN
WITH RHEUMATOID ARTHRITIS
C. Gøtestam Skorpen1,2, S. Lydersen1, I.M. Gilboe3, J.F. Skomsvoll1, K.Å. Salvesen1,
Ø. Palm3, H.S.S. Koksvik1, B. Jakobsen1, M. Wallenius1
(1Trondheim, Norway, 2Ålesund, Norway, 3Oslo, Norway)

PS4:79 LONG-TERM FOLLOW-UP OF 320 CHILDREN BORN TO MOTHERS WITH SYSTEMIC
AUTOIMMUNE DISEASES: A MULTICENTRE SURVEY FROM 24 RHEUMATOLOGY
CENTERS IN ITALY
M.G. Lazzaroni1, C. Nalli1, L. Andreoli1, C. Carini1, F. Dall'Ara1, M. Rodrigues2, E. Bartoloni Bocci3,
R. Gerli3, C.B. Chighizola4, M. Gerosa4, P.L. Meroni4, L. Sinigaglia4, P. Coniglio5,
R. Perricone5, A. Corrado6, F.P. Cantatore6, S. D'Angelo7, M. Favaro7, M. Lison7, A. Doria8,
A. Ruffatti8, E. Generali8, C.F. Selmi9, M. Meroni9, M. Cutolo9, M. Padovano10, M. Govoni10,
G. Pazzola11, C. Salvarani11, S. Peccatori12, I. Prevete5, G. Minisola5, G.D. Sebastiani5,
A.L. Brucato13, V. Ramoni13, R. Caporali14, C. Montecucco14, C. Tani15, V. Signorini15,
M. Mosca15, M. Trevisani15, N. Malavolta16, M. Vadacca15, A. Afeltra5, E. Vivaldelli17,
A. Maier17, E. Visalli17, R. Fotti18, L. Zuliani19, A. Gabrielli19, C. Campostrini19, E. Baldissera4,
M.G. Sabbadini19, N. Romeo20, A. Tincani20
(1Brescia, Italy, 2Coimbra, Portugal, 3Perugia, Italy, 4Milan, Italy, 5Rome, Italy,
6Foggia, Italy, 7Potenza, Italy, 8Padua, Italy, 9Genoa, Italy, 10Ferrara, Italy, 11Reggio Emilia, Italy,
12Trento, Italy, 13Bergamo, Italy, 14Pavia, Italy, 15Pisa, Italy, 16Bologna, Italy, 17Bolzano, Italy,
18Catania, Italy, 19Ancona, Italy, 20Cuneo, Italy)

PS4:80 HYDROXYCHLOROQUINE IN LUPUS PREGNANCY: A META-ANALYSIS OF
INDIVIDUAL PARTICIPANT DATA
A. Eudy1, M. Petri2, R. Fischer-Betz3, A. Mokbel4, C. Nalli5, L. Andreoli5, A. Tincani5, Y. Molad6,
D. D. Gladman7, M. Urowitz7
(1Durham, UK, 2Baltimore, USA, 3Düsseldorf, Germany, 4Cairo, Egypt, 5Brescia, Italy,
6Tel Aviv, Israel, 7Toronto, Canada)

PS4:81 QUALITY OF LIFE MAY INFLUENCE ON THE ABILITY TO ACHIEVE PREGNANCY IN
WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND WOMEN WITH RHEUMATOID
ARTHRITIS
C. Gøtestam Skorpen1,2, S. Lydersen1, I.M. Gilboe3, J.F. Skomsvoll1, K.Å. Salvesen1,
Ø. Palm3, H.S.S. Koksvik1, B. Jakobsen1, M. Wallenius1
(1Trondheim, Norway, 2Ålesund, Norway, 3Oslo, Norway)

PS4:82 LUPUS PREGNANCY: ACHIEVEMENTS AND OPEN ISSUES IN THE
MULTIDISCIPLINARY MANAGEMENT
F. Crisafulli1, L. Andreoli1, L. Antolini1, G. Parma1, C. Benigno2, A. Lojacono1, S. Zatti1,
V. Cappa1, S. Calza1, A. Tincani1
(1Brescia, Italy, 2Naples, Italy)
PS4:83 FOLLOW-UP OF NEWBORN BABIES FROM MOTHER AFFECTED BY SYSTEMIC AUTOIMMUNE DISEASE
T. Bertero, J. Munarin, M. Frigerio, E. Parodi
(Turin, Italy)

PS4:84 OBSTETRICAL COMPLICATIONS AND PREGNANCIES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
(Tunis, Tunisia)

PS4:85 FERTILITY AND PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A COMPARISON WITH OTHER RHEUMATIC DISEASES
(Valencia, Spain)

PS4:86 OBSTETRIC AND NEONATAL OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POPULATION-BASED REGISTER STUDY
L.S. Andersen, M. Bliddal, L.L. Andersen, A. Voss
(Odense, Denmark)

Poster Area, E-Poster Station 5
POSTER SESSION 5: INNATE AND ADAPTIVE IMMUNITY
Chairs: Z. Amoura (Paris, France), T. Dörner (Berlin, Germany)

PS5:87 JUVENILE-ONSET SLE IMMUNOPATHOGENESIS COULD BE ASSOCIATED WITH ALTERED IMMUNE CELL PLASMA MEMBRANE LIPIDS AND LIPOPROTEIN METABOLISM
G. Robinson, I. Pineda-Torra, Y. Ioannou, E.C. Jury
(London, UK)

PS5:88 ALTERED CELL SURFACE N-GLYCOSYLATION OF AUTOIMMUNE T-CELLS RESULTS IN DECREASED BINDING OF IMMUNOREGULATORY GALECTIN-1
L. Kovács, E. Szabó, Á. Hornung, É. Monostori, Á. Czibula
(Szeged, Hungary)

PS5:89 LOOKING FOR A SLE SIGNATURE ON PERIPHERAL B CELL SUBSETS: DOES A PREPONDERANT CD38 POSITIVE PLASMA BLAST-SUBPOPULATION LACK CD73 AS A SIGN OF A DIMINISHED B REGULATORY POOL?
(Düsseldorf, Germany)
PS5:90 ENHANCED IL-7 RECEPTOR SIGNALING IN SLE PROMOTES T-HELPER CELL PROLIFERATION THROUGH UPREGULATION OF MICRORNA-182 AND DOWNREGULATION OF FOXO1
(Berlin, Germany)

PS5:91 INCREASED EXPRESSION OF TLR7 IN PLASMACYTOID DENDRITIC CELLS DRIVES TYPE I IFN MEDIATED IMMUNOPATHOLOGY IN SLE AND APS
L.L. Van Den Hoogen¹, A. Pandit¹, G. Palla¹, M. Rossato¹, R.D.E. Fritsch-Stork², J.A.G. Van Roon¹, T.R. Radstake¹
(¹Utrecht, The Netherlands, ²Vienna, Austria)

PS5:92 CLARIFICATION OF THE ROLE OF DNASE 1 ON THE ONSET OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A MURINE MODEL
E. Kenny, U. Abu Abed, A. Kuehl, B. Raupach, V. Brinkmann, A. Zychlinsky
(Berlin, Germany)

PS5:93 MARGINAL-ZONE-LIKE B CELLS DEFICIENCY REPEATEDLY DETECTED IN PERIPHERAL BLOOD AS A POSSIBLE BIOMARKER OF HYPOSPLENISM/ASPLENIA IN SLE
(Hradec Králové, Czech Republic)

PS5:94 CHARACTERIZATION OF SLE B CELLS FROM PATIENTS IN REMISSION - PERSISTENT IL-10 SECRETORY DEFECT
(Düsseldorf, Germany)

PS5:95 CIRCULATING ANGIogenic T-CELLS ARE REDUCED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH HIGH DISEASE ACTIVITY AND WITHOUT KNOWN CARDIOVASCULAR RISK FACTORS
S. Piantoni¹, I. Cavazzana¹, M. Fredi¹, M. Taraborelli², F. Franceschini¹, A. Tincani¹, P. Airò¹
(¹Brescia, Italy, ²Chiari, Italy)

PS5:96 IL-21 DEPENDENT GRANZYME B PRODUCTION OF B-CELLS IS DECREASED IN PATIENTS WITH LUPUS NEPHRITIS
M. Rabani, B. Wilde, K. Hübbers, A. Kribben, O. Witzke, S. Dolff
(Essen, Germany)

PS5:97 ROLE OF CD107A+(LAMP-1) CYTOTOXIC CD8+ T-CELLS IN PATIENTS WITH SLE
A. Wiechmann, B. Wilde, A. Kribben, O. Witzke, S. Dolff
(Essen, Germany)

PS5:98 TCR ZETA DIM LYMPHOCYTES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
M. Szmyrka, L. Ciszak, A. Szteblich, M. Weglarz, A. Kosmaczewska
(Wroclaw, Poland)
PS5:99 EXAMINING THE MODULATORY EFFECTS OF ANTI-SERINE PROTEASE ANTIBODIES UPON FACTOR XA, THROMBIN AND COMPLEMENT INTERACTIONS
T. McDonnell¹, C. Wincup¹, V. Ripoll², C. Gerveshi², A. Rahman¹, I. Mackie¹, M. Botto¹, I. Giles³
(¹London, UK, ²Philadelphia, USA)

PS5:100 PATOPHYSIOLOGICAL ROLE OF TYPE I AND III INTERFERONS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
M. Meineck, A. Kommer, L. Schmidtke, J. Lutz, A. Schwarting, A. Pautz, J. Weinmann-Menke
(Mainz, Germany)

PS5:101 NUCLEAR ANTIGEN-REACTIVE CD4+ T CELLS ARE EXPAND ED IN ACTIVE SLE, CORRELATE WITH DISEASE ACTIVITY, INVADE TARGET ORGANS SUCH AS THE KIDNEYS, AND OUTNUMBER THEIR REGULATORY COUNTERPARTS
D. Abdirama¹, S. Tesch¹, A.S. Griessbach¹, A. Scheffold¹, A. Radbruch¹, U. Stervbo¹², N. Babel¹², G.R. Burmester¹, J.Y. Humrich³, G. Riemekasten³, P. Enghard¹
(¹Berlin, Germany, ²Bochum, Germany, ³Lübeck, Germany)

PS5:102 THE EXPRESSION OF BTLA ON CMV-SPECIFIC T-CELLS IS DECREASED IN CMV IGG+ PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
A. Savidis, B. Wilde, A. Kribben, O. Witzke, S. Dolff
(Essen, Germany)

PS5:103 COSTIMULATORY MAKER ON CYTOTOXIC CD8+ T-CELLS IN PATIENTS WITH SLE
C. Oster, B. Wilde, K. Hübers, A. Kribben, O. Witzke, S. Dolff
(Essen, Germany)

PS5:104 LYMPHOPENIA IN SYSTEMIC LUPUS ERYTHEMATOSUS - A RETROSPECTIVE ANALYSIS FROM UNIDADE IMUNOLOGIA CLINICA (CENTRO HOSPITALAR E UNIVERSITÁRIO DO PORTO)
T. Fonseca, A. Marinho, C. Vasconcelos, F. Farinha
(Porto, Portugal)

PS5:105 HDL INHIBITS T CELL PROLIFERATION IS SLE
M. Fernandes Das Neves¹, C. Favas¹, J. Batuca², E.C. Jury³, J. Delgado Alves¹²
(¹Amadora, Portugal, ²Lisbon, Portugal, ³London, UK)

PS5:106 LOW CIRCULATING BASOPHIL COUNTS IN BIOPSY-PROVEN ACTIVE LUPUS NEPHRITIS
I. Haddiya
(Oujda, Morocco)

PS5:107 DEFECTIVE REGULATION OF T FOLLICULAR HELPER CELLS BY ATP-GATED IONOTROPIC P2X7 RECEPTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS
R. Gualtierotti¹, C.E. Faliti¹², M. Gerosa¹, F. Grassi²¹, P.L. Meroni¹
(¹Milan, Italy, ²Bellinzona, Italy)

PS5:108 SEMAPHORIN3A: A BENEFICIAL THERAPY FOR LUPUS NEPHRITIS
E. Toubi, Z. Vadasz
(Haifa, Israel)
E-POSTER DISCUSSION (Friday 23 March, 12:30 - 14:00)

Poster Area, E-Poster Station 1
POSTER SESSION 6: MANAGEMENT AND RECOMMENDATIONS, DIAGNOSTIC AND CLASSIFICATION CRITERIA
Chairs: L. Arnaud (Strasbourg, Germany), C. Specker (Essen, Germany)

PS6:109 ASSOCIATION OF MENTAL HEALTH RELATED QUALITY OF LIFE (HRQOL) AND SUBSEQUENT PHYSICAL FUNCTIONING IN SYSTEMIC LUPUS ERYTHEMATOSUS: ANALYSIS OF DATA FROM THE GERMAN LULA COHORT 2002 - 2013
R. Brinks², G. Chehab¹, R. Fischer-Betz¹, J. Richter¹, R. Willers¹, B. Winkler-Rohlfing², M. Schneider¹
(¹Düsseldorf, Germany, ²Wuppertal, Germany)

PS6:110 MOTOR AND COGNITIVE FATIGUE IN SLE IS ASSOCIATED WITH MOOD AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH SLE: RESULTS FROM THE PATIENT REPORTED OUTCOMES IN LUPUS (PRO-LUPUS) STUDY
A. Bland¹, S. Hunziker², M. Barraclough¹, K. Kane¹, R. Cervera³, T. Dörner⁴, A. Doria⁵, J. Pouchot⁶, T. Stoll⁷, I.K. Penner⁸, I. Bruce¹
(¹Manchester, UK, ²Basel, Germany, ³Barcelona, Spain, ⁴Berlin, Germany, ⁵Padua, Italy, ⁶Paris, France, ⁷Schaaffhausen, Germany, ⁸Düsseldorf, Germany)

PS6:111 FORTY YEARS OF A LONDON LUPUS CLINIC – A RETROSPECTIVE ANALYSIS OF DRUG USE
B.S. Bernstein, T. McDonnell, C. Wincup, B. Tejera Segura, A. Rahman
(London, UK)

PS6:112 ACCEPTANCE AND COMMITMENT THERAPY IN LUPUS, A CASE CONTROL STUDY
M. Sahebari, A. Ahmadi, H. Aghamohammadian, M. Asghari, S.Z. Mirfeizi
(Mashhad, Iran)

PS6:113 LONG-TERM HYDROXYCHLOROQUINE USE: ARE LUPUS PATIENTS UNDERMONITORED? A UNIVERSITY TEACHING HOSPITAL EXPERIENCE
K. Sunmboye, S. Shaffu, M. Mccartney
(Leicester, UK)

PS6:114 HOW TO DIAGNOSE LUPUS ENTERITIS EARLY? LESSONS LEARNED FROM A MULTICENTER CASE SERIES
M. Luís¹, L. Brites¹, A.C. Duarte², V. Teixeira¹, C. Macieira¹, M.J. Santos², L.S. Sousa Ines¹
(¹Coimbra, Portugal, ²Lisbon, Portugal)

PS6:115 CYCLOPHOSPHAMIDE AS INDUCTION TREATMENT OF LUPUS NEPHRITIS IN A GROUP OF TUNISIAN PATIENTS: MONTHLY HIGH-DOSE OR BIWEEKLY LOW-DOSE PULSES?
(Tunis, Tunisia)
PS6:116 DIET HABITS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
(Split, Croatia)

PS6:118 OBJECTIVE MEASUREMENTS OF SLEEP DISORDERS AND PSYCHIATRIC COMORBIDITIES IN A COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
U. Faraguna1,2, C. Porciani1, R. Vagelli1, M. Di Galante2, C. Tani1, C. Stagnaro1, M. Mosca1
(1Pisa, Italy, 2Calambrone, Italy)

PS6:119 CLASS III-IV LUPUS NEPHRITIS MANAGEMENT IN EVERYDAY PRACTICE
S. Porta1, C. Aimo1, M. Micelli1, E. Kerzberg1, G. Ruiz-Irastorza2
(1Buenos Aires, Argentina, 2Barakaldo, Spain)

PS6:120 HAND ULTRASOUND GUIDED THERAPEUTIC DECISIONS IN INFLAMMATORY ARTHRITIS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN’S SYNDROME
L. Lei, S. Morgan, E. Ntatsaki, C. Ciurtin
(London, UK)

PS6:121 JUVENILE AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: A COMPARATIVE STUDY IN A COHORT OF TUNISIAN PATIENTS
(Tunis, Tunisia)

PS6:122 LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: CHARACTERISTICS AND COMPARISON WITH ADULT-ONSET DISEASE
(Tunis, Tunisia)

PS6:123 EXTENDED T2-TIMES IN CARDIOVASCULAR MAGNETIC RESONANCE (CMR) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND PERSISTED DYSPNOEA: IS SLE-ASSOCIATED MYOCARDITIS AN UNDERESTIMATED PROBLEM?
P. Sewerin, V. Lachmann, M. Gastl, P. Behm, R. Fischer-Betz, B. Ostendorf, G. Chehab, M. Schneider, F. Bönner
(Düsseldorf, Germany)

PS6:124 ALGORITHMS TO IDENTIFY SLE FROM EHR DATA
R. Ramsey-Goldman, T. Walunas, K. Jackson, A. Chung, D. Erickson, K. Mancera-Cuevas, A. Kho
(Chicago, USA)

PS6:125 SYSTEMIC LUPUS ERYTHEMATOSUS DIAGNOSIS IS EARLIER IN MALES COMPARED TO FEMALES
E. Gozcu, A. Karatas, B. Oz, S.S. Koca
(Elazig, Turkey)
PS6:126 AUTOIMMUNE CYTOPENIA IN SYSTEMIC LUPUS ERYTHEMATOSUS: EXPERIENCE OF A INTERNAL MEDICINE UNIT
G. Chalhoub
(Ars Laquenexy, France)

PS6:127 GENDER INFLUENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS
M. Kechida, R. Mesfar, R. Klii, S. Hammami, I. Khochtali
(Monastir, Tunisia)

PS6:128 INFLUENCE OF ASSOCIATED AUTO IMMUNE DISEASES IN SYSTEMIC LUPUS ERYTHEMATOSUS
M. Kechida, R. Mesfar, R. Klii, S. Hammami, I. Khochtali
(Monastir, Tunisia)

Poster Area, E-Poster Station 2
POSTER SESSION 7: NEW DRUGS & TRAGETED THERAPY
Chairs: A. Rahman (London, UK), A. Schwarting (Mainz, Germany)

PS7:129 SYNERGETIC B-CELL IMMUNOMODULATION WITH RITUXIMAB AND BELUMUMAB COMBINATION TREATMENT IN SEVERE, REFRACTORY SLE
T. Kraaij1, S.W.A. Kamerling1, E.N.M de Rooij1, P.L.A. Van Daele2, O.W. Bredewold1, J.A. Bakker1, I.M. Bajema1, H.U. Scherer1, R.E.M. Toes1, T.W.J. Huizinga1, T.J. Rabelink1, C. van Kooten1, Y.K.O. Teng1
(1Leiden, The Netherlands, 2Rotterdam, The Netherlands)

PS7:130 INTERFERON BETA BLOCKADE RESCUES HUMAN BM-MSC OSTEOBLASTOGENESIS DEFECTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
L. Gao, J. Anolik, R. Looney
(Rochester, USA)

PS7:131 EARLY SEQUENTIAL COMBINATION THERAPY WITH MIZORIBINE AND TACROLIMUS IN SIXTY THREE PATIENTS OF LUPUS NEPHRITIS IN A SINGLE CENTER IN JAPAN
M. Okada
(Tokyo, Japan)

PS7:132 SMOKING REDUCES THE EFFICACY OF BELUMUMAB IN MUCOCUTANEOUS LUPUS
I. Parodis1, A. Gomez1, C. Sjöwall2, A. Jönsen3, A. Zickert1, M. Frodlund2, A.A. Bengtsson3, I. Gunnarsson1
(1Stockholm, Sweden, 2Linköping, Sweden 3Lund, Sweden)

PS7:133 EXPOSURE-RESPONSE MODELLING AND EXPOSURE-SAFETY MODELLING ANALYSES IN TWO PHASE II STUDIES OF ATACICEPT IN SLE
O. Papasouliotis1, O. Yalkinoglu1, C. Vazquez-Mateo2, S. Wax2, A. Kao2, P. Chang2, P. Fleuranceau-Morel2, L. Mahnke2
(1Darmstadt, Germany, 2Billerica, USA)
PS7:134 RITUXIMAB-MEDIATED LATE-ONSET NEUTROPENIA IN SYSTEMIC LUPUS ERYTHEMATOSUS – DISTINCT ROLES OF BAFF AND APRIL

PS7:135 AMG 592 IS AN INVESTIGATIONAL IL-2 MUTEIN THAT INDUCES HIGHLY SELECTIVE EXPANSION OF REGULATORY T CELLS
N. Tchao¹, K.S. Gorski¹, T. Yuraszeck², S.J. Sohn¹, K. Ishida², H. Wong¹, K. Park³
(¹San Francisco, USA, ²Thousand Oaks, USA, ³Cambridge, UK)

PS7:136 APOPTOTIC EFFECT OF BLYS ON ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IS MEDIATED BY BLYS RECEPTORS AND IS REVERTED BY BELIMUMAB
F.R. Spinelli, C. Barbati, F. Ceccarelli, T. Colasanti, L. Massaro, F. Morello, C. Garufi, C. Alessandri, G. Valesini, F. Conti
(Rome, Italy)

PS7:137 THE USE OF BELIMUMAB IN RECALCITRANT CUTANEOUS LUPUS: A CASE REPORT
M. Gilio¹, G. Tramontano¹, M.S. Cutro¹, T. Carbone¹, V. Picerno¹, U. Bottoni², A. Padula¹, S. D’Angelo¹
(¹Potenza, Italy, ²Catanzaro, Italy)

PS7:138 NEW STRATEGY THERAPY FOR LUPUS NEPHRITIS WITH PERSISTENT PROTEINURIA
S. Algergawy
(Cairo, Egypt)

PS7:139 EFFICACY AND SAFETY OF RITUXIMAB IN RESISTANT SLE
R. Attar, O. Safdar, M. Muzaffar, S. Attar, M. Alhomeid
(Jeddah, Saudi Arabia)

PS7:140 BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS. 1 YEAR OF FOLLOW UP.
(Pamplona, Spain)

PS7:141 SAFETY AND TOLERABILITY OF OMAZUMAB IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY OUTCOMES
M. Davis, E. Poncio, Y. Temesgen-Oyelakin, Z. Manna, D. Chan, S. Gupta, M. Kaplan, S. Hasni
(Bethesda, USA)

PS7:142 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION IN A MONOCENTRIC SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT COHORT AND ITS CORRELATION TO ORGAN DAMAGE
A. Lladó, A.V. Taulaigo, M. Vicente, M.F. Moraes-Fontes
(Lisbon, Portugal)
PS7:143 SEVERITY ASSESSMENT OF LUPUS PATIENTS: DATA FROM THE LUPUS REGISTRY IN CRETE, GREECE
I. Gergianaki¹, A. Fanourakis², A. Repa¹, C. Adamichou¹, M. Terizaki¹, G. Spyrou¹, P. Sidiropoulos¹, D. Boumpas¹,², G. Bertsias¹
(¹Iraklio, Greece, ²Athens, Greece)

PS7:144 APPLICATION OF THE DORIS ALGORITHM FOR THE DEFINITION OF DISEASE REMISSION OVER A 2-YEAR PERIOD IN A COHORT OF ITALIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
F. Dall’Ara, L. Andreoli, F. Migliorati, G. Armentaro, M. Fredi, M. Frassi, F. Franceschini, S. Calza, A. Tincani
(Brescia, Italy)

PS7:145 IL-34, NOT CSF-1, SIMILARLY MEDIATES RHEUMATOID AND LUPUS ARTHRITIS IN PATIENTS
J. Weinmann-Menke¹, M. Meineck¹, L. Cavagna², C. Brochausen¹, V. Kelley³, A. Schwarting¹
(¹Mainz, Germany, ²Pavia, Italy, ³Boston, USA)

PS7:146 INVESTIGATION OF CHRONIC ORGAN DAMAGE AND DISEASE OUTCOME IN HUNGARIAN LUPUS PATIENTS
T. Tarr, G. Papp, N. Nagy, M. Zeher
(Debrecen, Hungary)

PS7:147 CLINICAL EXPERIENCE OF BELIMUMAB TREATMENT IN CLINICAL PRACTICE OF SLE PATIENTS
(Valencia, Spain)

PS7:148 THE RELATIONSHIP BETWEEN HYPOCOMPLEMENTEMIA AND HEMATOLOGICAL INVOLVEMENT IN ALBANIAN SLE PATIENTS
M. Jordhani, V. Duraj, D. Ruci, A. Kollcaku
(Tirana, Albania)

PS7:149 COLD COMPRESS FROM CASSAVA AS A NOVEL THERAPY TO PREVENT EXACERBATIONS AND IMPROVE QUALITY OF LIFE OF LUPUS PATIENTS WITH STRESS
E.S.D. Sari
(Malang, Indonesia)

PS8:151 HEMOPHAGOCYTIC SYNDROME IN PATIENTS FROM SLE REGISTRY FROM THE SPANISH SOCIETY OF RHEUMATOLOGY (RELESSER)
A. Lois Iglesias1, F.J. De Toro-Santos1, A. Zea Mendoza2, M. Galindo2, E. Uriarte3, I. Rua-Figueroa4, J.M. Pego-Reigosa5 (1A Coruña, Spain, 2Madrid, Spain, 3San Sebastián, Spain, 4Gran Canaria, Spain, 5Vigo, Spain)

PS8:152 TRENDS AND OUTCOMES OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM NATIONWIDE INPATIENT SAMPLE DATABASE 2003-2011
S. Kishore, V. Mittal, T. Nisar, S. Lirette, V. Majithia (Jackson, USA)

PS8:153 SUBTYPES AND LOCATION OF MYOCARDIAL INFARCTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
I. Samuelsson, I. Parodis, C. Anania, E. Svenungsson (Solna, Sweden)

PS8:154 THERAPEUTIC AND CARDIOVASCULAR DISEASE BURDEN IN UN DIFFERENTIATED CONNECTIVE TISSUE DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE LUPUS EXTENDED AUTOIMMUNE PHENOTYPE STUDY (LEAP) COHORT
S. Dyball, J. Reynolds, I. Bruce, B. Parker (Manchester, UK)

PS8:155 THE PREVALENCE OF HEAVY MENSTRUAL BLEEDING (MENORRHAGIA) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
C. Wincup, T. Richards, A. Rahman (London, UK)

PS8:156 HEMOPHAGOCYTIC SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS. A MONOCENTRIC STUDY OF 20 CASES.
W. Ammouri, N. Radi, S. Toumi, M. Bourkia, H. Khibri, M. Maamar, H. Harmouche, M. Adnaoui, Z. Tazi Mezalek (Rabat, Morocco)
PS8:157 IDENTIFYING THE RATES OF IRON DEFICIENCY AND ANAEMIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
C. Wincup, A. Rahman
(London, UK)

PS8:158 DEVELOPING A CAUSE DIFFERENTIATION OF FATIGUE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) – A RETROSPECTIVE SINGLE CENTRE ANALYSIS
C. Düsing, G. Chehab, J. Richter, H. Acar, R. Brinks, M. Schneider
(Düsseldorf, Germany)

PS8:159 MOVING WITH THE TIMES: SOCIAL MEDIA USE AMONGST LUPUS PATIENTS
(London, UK)

PS8:160 HEALTH CARE RESOURCE USE (HRU) AND MEDICAL COST ANALYSES AS A FUNCTION OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE SEVERITY: ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND
E.R. Hammond1, H. Freidel2, E. Garal-Pantaler2, M. Pignot3, E. Velthuis4, X. Wang1, H. Nab5, B. Desta1, A. Schwarting6
(1Gaithersburg, USA, 2Essen, Germany, 3Munich, Germany, 4Utrecht, The Netherlands, 5Cambridge, UK, 6Mainz, Germany)

PS8:161 THE DISEASE BURDEN IN PATIENTS WITH LONGSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS: FOCUS ON HEALTH RESOURCE USE AND COSTS
C. Tani, V. Lorenzoni, R. Vagelli, C. Stagnaro, E. Elefante, L. Carli, G. Turchetti, M. Mosca
(Pisa, Italy)

PS8:162 DISEASE PATTERN OF MALE LUPUS
N. Klyukvina, E. Nasonov
(Moscow, Russia)

PS8:163 CHARACTERISTICS AND OUTCOME OF LUPUS NEPHRITIS IN MOROCCO
I. Haddiya
(Oujda, Morocco)

PS8:164 COMPARISON OF CLINICAL AND SEROLOGICAL FEATURES OF JUVENILE AND ADULT-ONSET NEUROPSYCHIATRIC LUPUS IN SPANISH PATIENTS
(Madrid, Spain)

PS8:165 NEUROPSYCHIATRIC DAMAGE IN DECEASED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
I. Padjen, M. Erce, M. Cerovec, M. Mayer, R. Stevanovic, B. Anic
(Zagreb, Croatia)
PS8:166 COMPARISON OF CLINICAL AND SEROLOGICAL CHARACTERISTICS BETWEEN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH AND WITHOUT ASSOCIATED JACCOUD’S ARTHROPATHY
L. Villalobos Sánchez, A. Alía Jiménez, A. García Fernández, W.A. Sifuentes Giraldo, M.J. García Villanueva, M. Vázquez Díaz, A. Zea Mendoza
(Madrid, Spain)

PS8:167 THERAPEUTIC EFFICACY OF BELIMUMAB IN ADDITION TO STANDARD THERAPY FOR LUPUS NEPHRITIS AND NEUROPSYCHIATRIC LUPUS - CASE SERIES OF ROUTEPLY COLLECTED DATA AT A SINGLE CENTER
J.G. Rademacher, L.E. Schrempf, M. Plüß, G.A. Müller, P. Korsten
(Göttingen, Germany)

PS8:168 PROTEINURIA IN RELATION TO CLASS OF LUPUS NEPHRITIS A RETROSPECTIVE SINGLE-CENTER STUDY
L.E. Schrempf, J.G. Rademacher, M. Plüß, G.A. Müller, P. Korsten
(Göttingen, Germany)

PS8:169 PREVALENCE AND IMPACT OF DYSLIPIDEMIA IN LUPUS NEPHRITIS PATIENTS
I. Haddiya
(Oujda, Morocco)

PS8:170 LUPUS NEPHRITIS IN A MULTI-ETHNIC COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM BERKSHIRE, UNITED KINGDOM
S. Gindea, S. William
(Slough, UK)

PS8:171 ENDOTHELIAL DYSFUNCTION AND VASCULAR RISK FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
(Oviedo- Asturias, Spain)

Poster Area, E-Poster Station 4
POSTER SESSION 9: MISCELLENEA
Chairs: L. Andreoli (Brescia, Italy), E. Svenungsson (Stockholm, Sweden)

PS9:172 CHARACTERISTICS OF LUPUS NEPHRITIS IN SAUDI LUPUS PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY
I. Al-Homood, A. Almasmaly, M. Albirdisi
(Riyadh, Saudi Arabia)

PS9:173 TWO DECADES OF NEUROLUPUS
(Guimarães, Portugal)
PS9:174 PREVALENCE OF VASCULAR RISK FACTORS IN A COHORT STUDY OF PATIENTS IN FOLLOW-UP IN A UNIT OF AUTOIMMUNE DISEASES IN A 3TH LEVEL HOSPITAL IN SPAIN
(Oviedo- Asturias, Spain)

PS9:175 TWO DECADES OF LUPUS NEPHRITIS
(Guimarães, Portugal)

PS9:176 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS) TO CHARACTERIZE MODERATE TO SEVERE SLE DISEASE ACTIVITY, TREATMENT, AND OUTCOMES BY TYPE I INTERFERON GENE SIGNATURE
E.R. Hammond¹, R. Tummala¹, A. Berglind², B. Desta¹, H. Nab³
(¹Gaithersburg, USA, ²Gothenburg, Sweden, ³Cambridge, UK)

PS9:177 LUPUS NEPHRITIS - CLINICOPATHOLOGICAL CORRELATION AND RENAL OUTCOME
R. Rajasekharan Nair, P. Harish, S. Seethalekshmy, G. Kurian, A. Mathew, Z. Paul, S. Sreedharan
(Kochi, India)

PS9:178 REMOVAL OF AN ADRENAL HORMONE ADENOMA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND AUTOMATIC FRACTURES
G. Spiliotis
(Boula, Guinea Republic)

PS9:179 THE SIDE EFFECT AND THE RETENTION RATE OF HYDROXYCHLOROQUINE IN JAPAN
Y. Ikeda, R. Rokutanda, M. Okada
(Tokyo, Japan)

PS9:180 MANAGEMENT OF NON-RETINAL TOXICITY OF HYDROXYCHLOROQUINE
M. Okada, M. Suda
(Tokyo, Japan)

PS9:181 TYPE IV ALLERGY TO ANTIMALARIALS CAN MIMIC CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS
L. Borik, T. Quint, S. Wöhrl, T. Kinaciyan, P. Petzelbauer, P. Heil
(Vienna, Austria)
Poster Area, E-Poster Station 5
POSTER SESSION 10: DIFFICULT CASES
Chairs: D. Boumpas (Athens), A. Doria (Padua)

PS10:182 NMDA-POSITIVE NEUROPSYCHIATRIC LUPUS MANIFESTING AS WEIGHT INCREASE AND HYPOSMIA
C. Pamfil, S. Rednic, I. Catana, M. Deac Badarinza, D. Balint Gib, P. Vele, L. Bene, L. Damian
(Cluj-Napoca, Romania)

PS10:183 CHYLOUS ASCITES AND PODOCYTOPATHY AS PRESENTING FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A YOUNG CHILD
A. Gupta, S. Guleria, D. Suri, A. Gupta, A. Rawat, R. Nada, S. Singh
(Chandigarh, India)

PS10:184 CONstrictive PERICARDITIS AS THE FIRST PRESENTATION OF SYSTEMIC LUPUS Erythematous: A CASE REPORT AND LITERATURE REVIEW
H. Jethwa¹, M. Rana¹, J. Kitt², J. Democratis¹, S. Menzies¹, A. Steuer¹, S. Gindea¹
¹Slough, UK, ²South Buckinghamshire, UK)

PS10:185 NOdular localized CUTaneous AMYLOIDOSIS IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS
M. Deac Badarinza, S. Rednic, C. Pamfil, C. Baican, A. Vasilache, I. Filipescu, I. Muresan, D. Balint Gib, L. Damian
(Cluj-Napoca, Romania)

PS10:187 CAUSES OF DEATH IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY CARE CENTER, SOUTHERN THAILAND
P. Vachvanichsanong, E. Mcneil, P. Dissaneewate
(Hat Yai, Thailand)

PS10:189 NEUROPSYCHIATRIC LUPUS. A SEVERE MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS.
P. Athanassiou, C. Katsavouni, M. Gatsiou, A. Tzanavari, C. Gerodimos
(Thessaloniki, Greece)

PS10:190 UNUSUAL PRESENTATION OF LUPUS PROFUNDUS
P.D. Rath, A. Abrari, S. Budhiraja
(New Delhi, India)
### Room 3A  
**10:00-13:00**  
**DEVELOPMENT OF TARGETED THERAPIES IN RHEUMATOLOGY**  
Chairs: G. Pongratz (Düsseldorf, Germany), M. Schneider (Düsseldorf, Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 10:00-10:15     | **Introduction**  
M. Schneider (Düsseldorf, Germany)                                    |
| 10:15-10:45     | **What has impeded sle drug development: the drugs, the designs, or the designers?**  
R. Furie (New York, USA)                                        |
| 10:45-11:15     | **Dapirolizumab pegol - A potential novel treatment for SLE patients**  
C. Stach (UCB Pharma)                                         |
| 11:15-11:45     | **Coffee Break**                                                              |
| 11:45-12:15     | **JAK inhibitors and inflammatory diseases**  
P-A. Löschmann (Pfizer)                                          |
| 12:15-12:45     | **The future of rheum: innovations in rheumatology: where is the new frontier?**  
A.J. Long (AbbVie)                                              |
| 12:45-13:00     | **Effective lupus trials - Open space results**  
M. Schneider (Düsseldorf, Germany)                                |

*No CME activity*
SLEuro SECRETARIAT AND GENERAL ASSEMBLY
SLEuro Secretariat will be present for the whole congress at the registration desk in the building 23.01 – level 0.
The General Assembly of the European Lupus Society has been scheduled on Thursday 22 March at 18:30 in 3A room. During the General Assembly will be held the elections of the next Executive Committee for the years 2019-2020. A hostess will check the status of your membership outside 3A room.

ABSTRACT BOOK
All submitted abstracts, accepted as oral presentation or poster, have been published under the terms of BMJ’s exclusive license as a supplement to the Official Journal of Lupus 2018 "Lupus Science & Medicine".
The abstract book is available only in electronic format on line and downloadable from Lupus Science & Medicine website (www.lupus.bmj.com) within the beginning of the Congress.

PRE-MEETING COURSE (only for Trainees/Fellows)
A pre-meeting course, dedicated to the SLE interested fellows, will be held on March 21 from 10:00 to 15:00, before the official beginning of the conference. Here participants will learn all about SLE basics in three interactive workshops:
• Diagnosis of SLE and SLE mimics
• Therapeutic strategies in SLE
• Immunofluorescence microscopy or Capillary microscopy (to be chosen by the participant)
All participants attending the pre-meeting course are invited to reach the Registration area at 09:30 in order to collect the congress kit. A hostess will guide the group to the conference room of the course.
A box lunch will be served from 12:15 to 13:00 inside the room.
Speakers presenting in the pre-meeting course are requested to submit their presentation directly in the course room or to send it by e-mail in advance at lupus2018@aimgroup.eu

MENTOR-MENTEE-PROGRAM (only for Trainees/Fellows and Students)
During the Congress, young fellows will meet experts in SLE and get one mentor assigned that will guide them through the conference to resume the day, discuss interesting topics, visit the poster session and share the most exciting news.
A Welcome-meeting will be held on March 21 at 16:30 in the Poster Area.
A mentor will be assigned to each mentee and together will be introduced to the program. On the last day, March 24, a Feedback round will be organized at 13:00 in the Poster Area.
Scientific Information

FISHBOWL DISCUSSION ROUNDS
On March 22 and 23, interactive sessions called “Fishbowl and Open Chair – Discussion Rounds” will be organized throughout the meeting in the Poster area (Building 22.01). All the delegates are invited to choose their favorite topic.

What is fishbowl?
The fishbowl activity is a simple but effective method used to manage group discussion. The general idea is that rather than a large group having an open discussion, a smaller group of 3 to 6 participants is seated in an inner circle to discuss a specific topic while the rest of the participants sit in an outer circle observing the inner discussant. There is always one chair left empty in the center circle. This chair is open for someone from the observing plenum to step into to make a statement or ask a question and thus to take an active part in the discussion. There is one moderator that will frame the opening of the conversation and then let go. Moderating is supposed to be kept at a minimum.

„Fishbowl“ - the essence
- Discussion in inner circle
- Observing and thinking in outer circle
- Impulse from person on “empty chair”
- Moderator: guides through questions, reflections and summaries
- Recorder: summarizes results

Rules
- 4 participants + “empty chair” in inner circle
- Discussion only in inner circle
- Only one discussant in the inner circle talks at a time
- Each statement should relate to the previous contribution
- The empty chair in the inner circle enables the plenum to actively participate in the discussion by asking a question or expressing an opinion
- Members of the plenum on the free chair have immediate right to speak. After their statement, the members leave the inner circle and return to the outer circle
- The plenum observes, takes notes and participates actively on empty chair
- The moderator opens and moderates the discussion and watches the compliance with the rules
- The moderator intervenes only if necessary

POST-MEETING COURSE
The post meeting course will be held on Saturday, 24 March 2018 from 10:00 to 13:00 and it will focus on “Targeted Therapies in Rheumatology”. The course is included in the registration fee.
GUIDELINES FOR CHAIRPERSONS AND SPEAKERS

Guidelines for chairpersons

- Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session
- Respect the timing allowed to the session and to each presentation
- All presentations, discussions and questions must be in English

Guidelines for speakers

- Follow the instructions indicated in the paragraph “Audiovisual Instructions”
- Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session to meet the chairpersons
- Respect the timing allowed for your presentation
- All presentations, discussions and questions must be in English

Audiovisual instructions

Speakers presenting in oral sessions are requested to submit their presentations (16:9 format) to the slide centre at least 1 hour before the start of their session.

Personal computers cannot be connected to the projectors in the session room and presentations cannot be loaded directly on the computer of the session rooms.

If speakers created their presentation using a system different from Windows (such as OS MAC or Linux), they are kindly requested to provide presentations in a Windows-compatible format and to come earlier to the slide centre, in order to have enough time to solve possible compatibility issues.

At the slide centre our hostess will welcome and help speakers. Experienced technicians will assist speakers in transferring the slides and make changes if needed. Slide presentations will then be uploaded to the respective session room.

BEST PAPERS

The best 10 posters presented by authors under 40 will receive a prize during the Closing Ceremony. The selection will be done by the Chairs during the E-poster discussions.

ORAL COMMUNICATIONS

Oral presentations are limited to 7 minutes followed by 3 minutes of discussion. Participants presenting in oral sessions are requested to submit their presentations to the slide centre at least 1 hour before the start of their session.
E-POSTERS

All abstracts accepted as posters will be displayed at E-Poster Stations (LCD Screens). The discussion will take place in the Poster Area (Building 22.01, floor 0) during lunchtime on Thursday, March 22 from 12:00 to 13:30 and Friday, March 23 from 12:30 to 14:00. The electronic poster must be structured with 2 slides (1st slide: Objective, Design and Method - 2nd slide: Results and Conclusions) and each author has 3 minutes for the presentation and 1 minute for the discussion. The E-Poster Discussion during lunchtime will be guided and moderated by 2 Chairs. All presentations, discussions and questions must be in English.

E-POSTERS DISCUSSION SESSIONS

<table>
<thead>
<tr>
<th>E-Poster Station 1</th>
<th>E-Poster Station 2</th>
<th>E-Poster Station 3</th>
<th>E-Poster Station 4</th>
<th>E-Poster Station 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday, 22 March, Poster area Roy Lichtenstein - 12:00-13:30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster session 1: Autoantibodies, biomarkers and imaging (1) Posters from n. 1 to 22</td>
<td>Poster session 2: Autoantibodies, biomarkers and imaging (2), Environmental, epigenetics and genomics Posters from n. 23 to 44</td>
<td>Poster session 3: Epidemiology Posters from n. 45 to 65</td>
<td>Poster session 4: APS, Family planning, fertility, pregnancy and neonatal care Posters from n. 66 to 86</td>
<td>Poster session 5: Innate and adaptive immunity Posters from n. 87 to 108</td>
</tr>
<tr>
<td><strong>Friday, 23 March, Poster area Roy Lichtenstein - 12:30-14:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster session 6: Management and recommendations, Diagnostic and classification criteria Posters from n. 109 to 128</td>
<td>Poster session 7: New drugs &amp; targeted therapy Posters from n. 129 to 149</td>
<td>Poster session 8: Registries and cohorts Posters from n. 150 to 171</td>
<td>Poster session 9: Miscellanea Posters from n. 172 to 181</td>
<td>Poster session 10: Difficult cases Posters from n. 182 to 190</td>
</tr>
</tbody>
</table>
CME ACCREDITATION

An application has been made to the EACCME® for CME accreditation of this event.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Attendance is monitored through a scanner device in order to check learner’s entrance/exit each day (The presence is a main requirement to obtain credits).

Participants will receive their certificate of attendance once they have filled in the evaluation form. All the information will be sent by e-mail after the congress.

CME PROVIDER

AIM Education - Provider n. 93
Via G. Ripamonti, 129 - 20141 Milan, Italy
Ph. +39 02 56601.1 - Fax +39 02 70048585
cme@aimgroup.eu - www.aimeducation.it
General Information

ORGANIZING SECRETARIAT

AIM Group International - Milan Office
Via G. Ripamonti, 129 - 20141 Milan, Italy
Ph. +39 02 566011 - Fax +39 02 70048578
www.lupus2018.com

general information and abstract: lupus2018@aimgroup.eu
registrations: lupus2018.reg@aimgroup.eu
accommodation: lupus2018.hotel@aimgroup.eu

CONGRESS VENUE

Heinrich Heine University of Düsseldorf
Universitätsstraße 1 - 40225 Düsseldorf, Germany
Building 23.01 (closest bus stop: Universität-Mensa)

HOW TO REACH THE VENUE

Arriving by plane
Düsseldorf Rhine-Ruhr airport is one of the biggest in Europe. There is a good connection to the main station by city train (S-Bahn) and from there to the University by tram (line U79 to the stop “Südpark”, line 731, 735, 827, NE7 to the stop Universität-Mensa).

Arriving by train
Düsseldorf main station is connected to all international long-distance train routes. Both the U79 and the 704 tram go from there directly to the University. Travel time from the station is around 20 minutes.
Line U79: stop at “Südpark”
Lines 731, 735, 827, NE7: stop at Universität-Mensa.
Line 704: stop at "Uni-Nord / Christophstraße"

Arriving by bus
The University is on the route of the following buses: 735, 827, 835 and 836. If you take the 735 or 827 you can get off at “Universität Mensa” (the closest bus stop).
General Information

MAP OF HEINRICH HEINE UNIVERSITY CAMPUS

Legend
- Parking
- Disabled Parking
- Cafeteria
- Cash Machine

PRE-COURSE MEETING VENUE

LUNCH & POSTER AREA

MAIN CONFERENCE VENUE

Legend:
- Parking
- Disabled Parking
- Cafeteria
- Cash Machine

MAP OF HEINRICH HEINE UNIVERSITY CAMPUS

General Information

MAP OF HEINRICH HEINE UNIVERSITY CAMPUS

Legend
- Parking
- Disabled Parking
- Cafeteria
- Cash Machine

PRE-COURSE MEETING VENUE

LUNCH & POSTER AREA

MAIN CONFERENCE VENUE
FLOORPLAN - Building 23.01

LEVEL -1

- MEETING ROOM
- SLIDE CENTRE & MEETING ROOMS

LEVEL 0

- ACCESS TO LEVEL -1
- CLOAKROOM
- REGISTRATION AREA
- ENTRANCE

EXHIBITORS

<table>
<thead>
<tr>
<th>EXHIBITORS</th>
<th>SPACE</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>5</td>
</tr>
<tr>
<td>Biogen</td>
<td>15</td>
</tr>
<tr>
<td>Celgene</td>
<td>7</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>6</td>
</tr>
<tr>
<td>Euroimmun</td>
<td>22</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>8 - 9 - 10 - 11 - 12</td>
</tr>
<tr>
<td></td>
<td>16 - 17 - 18 - 19 - 20</td>
</tr>
<tr>
<td>Janssen-Cilag GmbH</td>
<td>14</td>
</tr>
<tr>
<td>F. Hoffmann La Roche Ltd</td>
<td>13</td>
</tr>
<tr>
<td>Sanofi-Aventis Deutschland GmbH</td>
<td>21</td>
</tr>
</tbody>
</table>
General Information

FLOORPLAN - Building 22.01

LEVEL 0

LEVEL -1
OPENING HOURS

<table>
<thead>
<tr>
<th>Date</th>
<th>Registration Desk</th>
<th>Exhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, 21 March, 2018</td>
<td>13:00 - 20:00</td>
<td>16:00 - 21:00</td>
</tr>
<tr>
<td>Thursday, 22 March, 2018</td>
<td>08:00 - 19:30</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Friday, 23 March, 2018</td>
<td>07:30 - 19:00</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Saturday, 24 March, 2018</td>
<td>08:30 - 13:30</td>
<td>09:00 - 13:00</td>
</tr>
</tbody>
</table>

LANGUAGE

The official language is English. No simultaneous translation will be provided.

ADMISSION

Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunches.

What colour is your badge?

- Participants: TRANSPARENT
- Faculty: RED
- Exhibitors and Press: GREEN

ATTENDANCE CERTIFICATES

Attendance certificates will be sent by e-mail the last day of the Congress to all regularly registered participants.

OPENING CEREMONY AND WELCOME COCKTAIL

The Opening Ceremony of the Congress will be held on March 21 at 17.00 in the 3A Room. The Welcome Cocktail will be held on March 21 starting from 20.00 in the exhibition area.

COFFEE BREAKS AND LUNCHES

Coffee breaks will be offered in the exhibition area (Building 23.02, floor -1) as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Morning</th>
<th>Afternoon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 22 March, 2018</td>
<td>10:00 - 10:20</td>
<td>16:20 - 16:50</td>
</tr>
<tr>
<td>Friday, 23 March, 2018</td>
<td>10:30 - 10:50</td>
<td>16:20 - 16:50</td>
</tr>
<tr>
<td>Saturday, 24 March, 2018</td>
<td>11:15 - 11:45</td>
<td>-</td>
</tr>
</tbody>
</table>

A buffet lunch will be offered in the lunch area (Building 22.01, Floor -1) as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 22 March, 2018</td>
<td>12:00 - 13:30</td>
</tr>
<tr>
<td>Friday, 23 March, 2018</td>
<td>12:30 - 14:00</td>
</tr>
</tbody>
</table>
General Information

COUNTRY FLAG MONITORS
At the entrance, near the Registration Area, you can find two country flags monitors. Touch the screen and find out who is attending the Congress.

CLOAKROOM
Cloakroom and luggage storage facilities are available in the congress venue.

WI-FI 📱
Free Wi-Fi is available in the Congress area.
The network name is HHU-GAST and each participant will have to enter the login name LUPUS2018 and password HHU2018 in a web frontend.

TRANSPORTATION CARDS
All participants who made the reservation of the room with the Official Housing Bureau and Travel Agency of the congress have received by e-mail a public transportation ticket valid Wednesday–Saturday, 21–24 March 2018, within Düsseldorf. Please note that this ticket covers the transportation from and to the airport.

OFFICIAL CARRIER
Lufthansa Group Partner Airlines is the official carriers of LUPUS 2018. It offers a comprehensive global route network linking major cities around the world, and special prices and conditions to participants, visitors, exhibitors, invited guests as well as employees of the Contracting partner and their travel companions.

INSURANCE
Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.

BATTERY MULTI-CHARGER
At the GSK booth you can find a battery multi-charger where you can charge your mobile phone, smartphone, tablet, etc. It’s highly safe because each user can lock the device in a small cabinet with a plug and keep the key.
**REGISTRATIONS**

<table>
<thead>
<tr>
<th>REGISTRATION FEE (All fees are German VAT 19% included)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DELEGATE - SLEuro member</td>
<td>€ 650,00</td>
</tr>
<tr>
<td>DELEGATE - non member</td>
<td>€ 700,00</td>
</tr>
<tr>
<td>STUDENT*</td>
<td>€ 310,00</td>
</tr>
<tr>
<td>TRAINEE/FELLOW*</td>
<td>€ 310,00</td>
</tr>
<tr>
<td>HEALTH PROFESSIONAL*</td>
<td>€ 370,00</td>
</tr>
<tr>
<td>PATIENT</td>
<td>€ 30,00</td>
</tr>
<tr>
<td>CONGRESS COURSE (only for those will not attend the congress)</td>
<td>€ 120,00</td>
</tr>
</tbody>
</table>

* In order to benefit from the special fee, the delegate is asked to submit the status confirmation (approval letter signed by the Head of Department or copy of your status ID) at the registration desk.

**PAYMENTS**

Payments onsite are possible in cash (in Euro) or by credit card (American Express, VISA, Eurocard/Master Card). Please note that due to the Italian Law, it is forbidden to transfer cash between different subjects for an amount exceeding € 3,000,00.

**Name Changes**

Name changes onsite are subject to an handling fee of € 50,00 (VAT 19% included). A new registration form for each replacement will be required.

**SOCIAL DINNER**

Friday, March 23 at 20:30 at Sammlung Philara
(for the faculty and registered participants who bought the ticket - € 100,00 VAT included)

Please note that the number of participants for this event is limited. Ask to the Registration Desk if some places are still available.

Registrations to the Social Dinner will be treated on a first-come first-served basis.
General Information

SOCIAL MEDIA
Connect with SLEuro Society and LUPUS 2018 on social media. Be the first to learn about news, events and important updates, and share your opinions with us.

Our channels are geared towards patients and persons interested in learning more about Lupus disease.

Follow us on Facebook and Twitter
#SLEuro  #lupus2018  #LupusMeeting

NO-SMOKING
Smoking in the meeting area is not allowed.

MOBILE PHONES
Delegates are kindly requested to set their mobile phones on silent mode in the halls where scientific sessions are being held.

PRIVACY DISCLOSURE AND PUBLISHING OF IMAGES
Pursuant to article 13 of Legislative Decree no. 196/2003, the personal data of the participants, their videos and photos made during the event, will be used by AIM Italy s.r.l. for purposes related to the communication and the valorization of the event.

Such personal data will be communicated only to those people who are in charge of the activities necessary to the aforementioned purposes. Photos and videos will be also published on the website and social networks of AIM Group International (and on the website and social networks of the event, if any).

The treatment will be carried out with appropriate tools ensuring security and confidentiality and may be also carried out by computerized tools that are able to memorize, manage and transmit the personal data.

The data controller is AIM Italy s.r.l., with legal seat in Milan, Via Giuseppe Ripamonti 129, vat no. 00943621003, e-mail address info.aimcongress@aimgroup.eu.

With regard to the personal data granted, included photos and videos, each participant can exercise the rights set forth in article 7 of Legislative Decree n. 196/2003 by contacting the data controller.
ACCOMODATION

Hotel list:
1. LEONARDO ROYAL KONIGSALLEE ****
   Graf Adolf Platz, 8
2. LEONARDO CITY CENTER ****
   Ludwig Erhard Allee, 3
3. ME AND ALL HOTEL DUSSELDORF ****
   Immermannstrasse, 23
4. HOTEL NIKKO DUSSELDORF ****
   Immermannstrasse, 41

For any information and/or reservation please contact the Official Housing Bureau and Travel Agency of the congress:
AIM Group International
Phone: +39 02 566011
E-mail: lupus2018.hotel@aimgroup.eu
Managing the patient burden of SLE
Matthias Schneider

From trial design to clinical practice: The story of subcutaneous Benlysta (belimumab)
Andreas Schwarting

Meeting Gabriella: An interactive case study
Roger A. Levy (Chair)
Sponsored Session

CLINICAL TRIAL SESSION

FRIDAY 23 MARCH 2018

Room 3A
08:00-09:00

CUTANEOUS LUPUS ERYTHEMATOSUS: THE CROSSROAD BETWEEN RHEUMATOLOGY AND DERMATOLOGY

CLE – Clinical presentation and unmet need
J. Wenzel (Bonn, Germany)

pDCs in SLE and CLE
L. Rönnblom (Uppsala, Sweden)

INF pathway trials to date, with a focus on CLE
R. Furie (New York, USA)
SATELLITE SYMPOSIUM

FRIDAY 23 MARCH 2018

Room 3A
14:00-15:00  UNMET NEEDS IN THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Chair: M. Schneider (Düsseldorf, Germany)

Speakers:
E. Morand (Clayton, Australia)
R. Furie (New York, USA)
Fighting Serious Diseases

At Bristol-Myers Squibb, our commitment to develop innovative medicines is as strong as the patient’s will to fight serious diseases.

Our researchers are working every day to discover the next generation of treatments in areas such as:

• Cardiovascular
• Fibrotic Diseases
• Immuno-Oncology
• Immunoscience
• Oncology

To learn more about our commitment to patients around the world, visit www.bms.com

Bristol-Myers Squibb is proud to support the 11th Euro
“Having lupus is no longer a reason to give up. With today’s treatment you can pretty much have a normal life. So make sure you take your daily medicines and then enjoy life to the full without additional worries. And always remember: when it comes to lupus treatments, the best is yet to come.”

Bernadette, living with lupus

UCB has a passionate, long-term commitment to help patients and families living with severe diseases lead normal, everyday lives.

Our ambition is to offer them innovative new medicines and ground-breaking solutions in two main therapeutic areas: neurology and immunology. We foster cutting-edge scientific research that is guided by patients’ needs.
You can pretty much have a normal life. So make sure you take your daily medicines and then enjoy life to the full without additional worries. And always remember: when it comes to lupus treatments, the best is yet to come.”

Bernadette, living with lupus

UCB has a passionate, long-term commitment to help patients and families living with severe diseases lead normal, everyday lives.

main therapeutic areas: neurology and immunology. We foster cutting-edge scientific research that is guided by patients’ needs.
<table>
<thead>
<tr>
<th>Authors Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Houman M.H.   35, 41, 44, 45</td>
</tr>
<tr>
<td>Houssiau F.  15, 18</td>
</tr>
<tr>
<td>Hoyer B.  13</td>
</tr>
<tr>
<td>Hrncir Z.  42</td>
</tr>
<tr>
<td>Hsu B.  28</td>
</tr>
<tr>
<td>Hübbers K.  42, 43</td>
</tr>
<tr>
<td>Huizinga T.W.J.  46</td>
</tr>
<tr>
<td>Hultin Rosenberg L.  21</td>
</tr>
<tr>
<td>Humrich J.Y.  15, 43</td>
</tr>
<tr>
<td>Hunziker S.  44</td>
</tr>
<tr>
<td>Huynh-Do U.  16, 25</td>
</tr>
<tr>
<td>Iaccarino L.  13</td>
</tr>
<tr>
<td>Ibáñez Bosch R.  47</td>
</tr>
<tr>
<td>Idda L.  21</td>
</tr>
<tr>
<td>Ikeda Y.  52</td>
</tr>
<tr>
<td>Ioannou Y.  41</td>
</tr>
<tr>
<td>Iordache C.  32</td>
</tr>
<tr>
<td>Isenberg D.  14, 20, 24, 28</td>
</tr>
<tr>
<td>Iwamoto T.  30</td>
</tr>
<tr>
<td>Jackson K.  45</td>
</tr>
<tr>
<td>Jacobsen S.  20, 25, 29, 35</td>
</tr>
<tr>
<td>Jakobi B.  32</td>
</tr>
<tr>
<td>Jakobsen B.  40</td>
</tr>
<tr>
<td>Jayne D.  15, 18, 24</td>
</tr>
<tr>
<td>Jensen M.A.  30</td>
</tr>
<tr>
<td>Jeremic I.  16</td>
</tr>
<tr>
<td>Jethwa H.  53</td>
</tr>
<tr>
<td>Jindal A.  39</td>
</tr>
<tr>
<td>Jonkman M.F.  30</td>
</tr>
<tr>
<td>Jönsen A.  20, 21, 46</td>
</tr>
<tr>
<td>Joo Y.B.  37</td>
</tr>
<tr>
<td>Jordanova E.S.  15</td>
</tr>
<tr>
<td>Jordhan M.  48</td>
</tr>
<tr>
<td>Jorge I.  37</td>
</tr>
<tr>
<td>Juarez M.  12</td>
</tr>
<tr>
<td>Jung H.J.  37</td>
</tr>
<tr>
<td>Jung J.  33</td>
</tr>
<tr>
<td>Jury E.C.  41, 43</td>
</tr>
<tr>
<td>Kachakova D.  35</td>
</tr>
<tr>
<td>Kalden J.  16</td>
</tr>
<tr>
<td>Kallenber C.  13</td>
</tr>
<tr>
<td>Kallinich T.  31</td>
</tr>
<tr>
<td>Kamerling S.W.A.  46</td>
</tr>
<tr>
<td>Kane K.  44</td>
</tr>
<tr>
<td>Kaneva R.  35</td>
</tr>
<tr>
<td>Kao A.  28, 46</td>
</tr>
<tr>
<td>Kaplan M.  47</td>
</tr>
<tr>
<td>Kappos L.  25</td>
</tr>
<tr>
<td>Karageorgou D.  17</td>
</tr>
<tr>
<td>Karatas A.  45</td>
</tr>
<tr>
<td>Karlsson Å.  21</td>
</tr>
<tr>
<td>Kastbom A.  39</td>
</tr>
<tr>
<td>Kasza Z.  47</td>
</tr>
<tr>
<td>Katsavouni C.  38, 53</td>
</tr>
<tr>
<td>Kavroulakis E.  17</td>
</tr>
<tr>
<td>Kecheda M.  34, 46</td>
</tr>
<tr>
<td>Kelley V.  48</td>
</tr>
<tr>
<td>Kenny E.  42</td>
</tr>
<tr>
<td>Kerick M.  12</td>
</tr>
<tr>
<td>Kerzberg E.  45</td>
</tr>
<tr>
<td>Khamashta M.  17, 21</td>
</tr>
<tr>
<td>Khawaja A.  25</td>
</tr>
<tr>
<td>Khawaja M.  38</td>
</tr>
<tr>
<td>Khibri H.  49</td>
</tr>
<tr>
<td>Kho A.  45</td>
</tr>
<tr>
<td>Khochtali I.  34, 46</td>
</tr>
<tr>
<td>Khodadadi L.  13</td>
</tr>
<tr>
<td>Kikuchi-Taura A.  34</td>
</tr>
<tr>
<td>Kim D.  37</td>
</tr>
<tr>
<td>Kim H.  33</td>
</tr>
<tr>
<td>Kim W.  38</td>
</tr>
<tr>
<td>Kinaciyan T.  52</td>
</tr>
<tr>
<td>Kishore S.  36, 49</td>
</tr>
<tr>
<td>Kiss E.  17</td>
</tr>
<tr>
<td>Kitt J.  53</td>
</tr>
<tr>
<td>Klili R.  34, 46</td>
</tr>
<tr>
<td>Kliminski V.  17</td>
</tr>
<tr>
<td>Klotsche J.  13, 31</td>
</tr>
<tr>
<td>Klyukvina N.  50</td>
</tr>
<tr>
<td>Koca S.S.  45</td>
</tr>
<tr>
<td>Koenig K.F.  25</td>
</tr>
<tr>
<td>Koksvik H.S.S.  40</td>
</tr>
<tr>
<td>Kollcaku A.  48</td>
</tr>
<tr>
<td>Komer A.  43</td>
</tr>
<tr>
<td>Konstantonis G.  38</td>
</tr>
<tr>
<td>Korkmaz C.  37</td>
</tr>
<tr>
<td>Korsten P.  35, 39, 51</td>
</tr>
<tr>
<td>Kosalka J.  32</td>
</tr>
<tr>
<td>Kosmaczewska A.  42</td>
</tr>
<tr>
<td>Kostoglou-Athanassiou I.  38</td>
</tr>
<tr>
<td>Koteli A.  38</td>
</tr>
<tr>
<td>Kountouri A.  36</td>
</tr>
<tr>
<td>Koutsilieris M.  38</td>
</tr>
<tr>
<td>Kovács L.  41</td>
</tr>
<tr>
<td>Kozyrev S.  21</td>
</tr>
<tr>
<td>Kraaij T.  46</td>
</tr>
<tr>
<td>Kravarit E.  38</td>
</tr>
<tr>
<td>Kribben A.  42, 43</td>
</tr>
<tr>
<td>Kuehl A.  42</td>
</tr>
<tr>
<td>Kumánoivos G.  36</td>
</tr>
<tr>
<td>Kumar R.  28</td>
</tr>
<tr>
<td>Kurian G.  52</td>
</tr>
<tr>
<td>Kuzuya K.  34</td>
</tr>
<tr>
<td>Kvarnström M.  33</td>
</tr>
<tr>
<td>Kvit A.  36</td>
</tr>
<tr>
<td>Labrador Sanchez E.  31, 32, 34, 41, 48</td>
</tr>
<tr>
<td>Lachmann V.  45</td>
</tr>
<tr>
<td>Lalmohamed A.  24</td>
</tr>
<tr>
<td>Lambers W.  30</td>
</tr>
<tr>
<td>Lamoulou M.  35, 41, 44, 45</td>
</tr>
<tr>
<td>Lange T.  35</td>
</tr>
<tr>
<td>Lara-Reyes P.  36</td>
</tr>
<tr>
<td>Laria A.  40</td>
</tr>
<tr>
<td>Larosa M.  13, 40</td>
</tr>
<tr>
<td>Laurent S.A.  31</td>
</tr>
<tr>
<td>Lazzaro E.  16, 24</td>
</tr>
<tr>
<td>Lazzaroni M.G.  40</td>
</tr>
<tr>
<td>Lecourt A.C.  25</td>
</tr>
<tr>
<td>Lee S.  33, 37</td>
</tr>
<tr>
<td>Lee S.W.  38</td>
</tr>
<tr>
<td>Leffers H.  35</td>
</tr>
<tr>
<td>Lei L.  45</td>
</tr>
<tr>
<td>Leonard D.  20, 21, 31</td>
</tr>
<tr>
<td>Lerang K.  12, 37</td>
</tr>
<tr>
<td>Lerström K.  19, 27</td>
</tr>
<tr>
<td>Levy R.A.  69</td>
</tr>
<tr>
<td>Lewis M.  35, 50</td>
</tr>
<tr>
<td>Li M.  17</td>
</tr>
<tr>
<td>Lindblad-Toh K.  21</td>
</tr>
<tr>
<td>Lipsky P.  28</td>
</tr>
<tr>
<td>Lirette S.  36, 49</td>
</tr>
<tr>
<td>Lisander Larsen J.  29</td>
</tr>
<tr>
<td>Lladó A.  24, 47</td>
</tr>
<tr>
<td>Lois Iglesias A.  23, 49</td>
</tr>
<tr>
<td>Lojacono A.  40</td>
</tr>
<tr>
<td>Long A.J.  54</td>
</tr>
<tr>
<td>Looney R.  46</td>
</tr>
<tr>
<td>Lopes J.M.  39</td>
</tr>
<tr>
<td>López Díaz P.  38</td>
</tr>
<tr>
<td>López-Longo F.J.  23, 36, 49</td>
</tr>
<tr>
<td>López Suárez P.  51, 52</td>
</tr>
<tr>
<td>Lorenz H.  16, 18</td>
</tr>
<tr>
<td>Lorenzoni V.  50</td>
</tr>
</tbody>
</table>
Authors Index

Löschmann P-A. 54
Lowin T. 28
Loza Cortina E. 47
Luisetto R. 28
Luis M. 44
Lundström E. 21
Lurati A. 40
Lüthke K. 35
Lutz J. 43
Lydersen S. 40

M
Maamar M. 49
Macieira C. 44
Mackie I. 43
Madan R. 33
Magder L. 14, 38, 39
Maggioni G. 28
Magoni M. 39
Mahler M. 35
Mahnke L. 46
Maier A. 40
Majithia V. 36, 49
Makol A. 30
Mala volta N. 40
Mancera-Cuevas K. 45
Mancini R. 22, 33
Manfredi A. 39
Manna Z. 47
Manteca C.F 47
Masarovic Krstulovic D. 45
Margiotta D.P. 36
Marinho A. 43
Marte J. 33
Martínez-Cordellat I. 31, 32, 34, 41, 48
Martínez-Taboada V. 49
Martínez Zapico A. 38, 51, 52
Martin J. 12, 31
Martinovic Kaliterna D. 45
Mashreghi F. 42
Masoumi N. 15
Massarenti L. 35
Massaro L. 22, 47
Mathew A. 52
Mathieu A. 21
Mathioudaki A. 21
Matsuo ka H. 34
Matsushita M. 34
Mavragani C. 38
Mayer M. 50
Mazzzone A. 40
Mccartney M. 44
McDonnell T. 26, 29, 34, 43, 44
Mcneil E. 53
Meadows J. 21
Medina-Gomez J.V. 36
Meineck M. 43, 48
Meinl E. 31
Meisel C. 31
Melero R. 49
Mendes C. 39
Mendizabal Mateos J. 47
Meneses J. 39
Menzies S. 53
Meroni M. 40
Meroni P.L. 32, 36, 40, 43
Merril J.T. 28
Mesfar R. 34, 46
Messa P. 15
Micelli M. 45
Middeldorp J.M. 15
Migniorati F. 48
Minisola G. 40
Miranda A.J. 37
Miranda F. 33, 34
Mirfeizi S.Z. 31, 37, 44
Miteva P. 35
Mittal V. 49
Mituo T. 32
Mobarak F. 16
Moder K.G. 30, 34
Moe S.E.R. 37
Mokbel A. 40
Molad Y. 17, 40
Molberg Ø. 12, 37
Monostori É. 41
Monova D. 35
Monov S. 35
Montecucco C. 40
Montilla C. 49
Moraes-Fontes M.F. 24, 37, 47
Morand E. 20, 28, 71
Morel L. 25
Morel T. 27
Morell M. 25
Morello F. 47
Morgan S. 45
Moroni G. 15, 32
Mosca M. 14, 19, 28, 36, 40, 45, 50
Moscarelli E. 33
Mota C. 39
Mourino C. 49
Moutsopoulos H.M. 17
Müller G.A. 35, 39, 51
Munarin J. 41
Murén E. 21
Muresan I. 53
Musial J. 32
Muzaffar M. 47

N
Nab H. 50, 52
Naceur I. 35, 41, 45
Nada R. 53
Nagy G. 36
Nagy N. 48
Najera Herranz C. 31, 32, 34, 41, 48
Nalli C. 39, 40
Nalotto L. 13
Naranjo A. 23
Narváez J. 49
Nasir T. 36
Nasonov E. 50
Natalucci F. 22
Negueroles Albuixech R. 31, 32, 34, 41, 48
Nehring J. 16
Nguyen M. 29
Nielsen C.H. 35
Niewold T.B. 22, 30
Nikolaou C. 21
Nikolopoulos D. 37
Nisar T. 49
Norby G.E. 32
Nordin J. 21
Nordmark G. 21, 31
Norton Y. 18, 26
Novelli L. 31
Ntatsaki E. 45

O
Ocampo-Torres M.C. 36
Ødum N. 35
Oguro E. 34
Ohshima S. 34
Okada M. 46, 52
Oke V. 21, 22, 33
Okita Y. 34
Olivé A. 36, 49
Authors Index

Oliveira S. 31
Oller Rodriguez J.E. 31, 32, 34, 41, 48
O’neill S. 17
Orrú V. 21
Ortiz Sanjuan F.M. 31, 32, 34, 41, 48
Osborn T. 30
Osmani Z. 18
Ospondorf B. 45
Oster C. 43
Oz B. 45
Ozdemir Isik O. 33
Padjen I. 50
Padovan M. 40
Padovani A. 30
Padula A. 47
Padyukov L. 21
Paetzel A. 12
Paglionico A. 31
Paiu R. 32
Pakozdi A. 35, 50
Palla G. 42
Palm Ø. 40
Pamfil C. 53
Pandit A. 42
Paniagua Zudaire I. 47
Papadaki E. 17
Papasouliotis O. 46
Papp G. 48
Parfenova M. 30
Parker B. 49
Park K. 47
Park Y. 38
Parma G. 40
Parnell C. 29
Parodi E. 41
Parodis I. 46, 47, 49
Parvu M. 20
Pascariello G. 39
Patarata E. 24
Paul Z. 52
Pauz A. 43
Pavlidis P. 21
Pazzola G. 40
Pecani A. 33
Peccatori S. 40
Pedersen H.L. 32
Pego-Reigosa J.M. 14, 18, 23, 28, 36, 49
Pegtel D.M. 15
Pendolino M. 22
Penner I.K. 44
Penserga E.G. 37
Pérez Álvarez A.I. 38, 51, 52
Perez Velasquez C.E. 30
Perkovic D. 45
Perricone C. 22, 31, 33
Perricone R. 31, 40
Pers J.O. 12
Petricca L. 31
Petric M. 45
Petri M. 14, 23, 36, 38, 39, 40
Petzelbauer P. 52
Piantoni S. 28, 42
Picerno V. 47
Pielberg G. 21
Pierro L. 36
Pieruzzi F. 15
Piga M. 21
Pignot M. 50
Pilania R. 39
Pineda-Torra I. 41
Pires A.S.X. 51, 52
Pisetsky D. 16
Pitzalis M. 21
Plüß M. 39, 51
Pokroy-Shapira E. 17
Pomirleanu C. 32
Poncio E. 47
Pongratz G. 28, 33, 41, 42, 54
Pons-Estel B. 20
Pontisso P. 28
Poor G. 17
Popova V. 35
Porciani C. 45
Porta S. 45
Pouchot J. 44
Prevete I. 40
Pri-Paz Basson Y. 17
Pröbstel A. 25
Proscura E. 25
Pyne D. 35, 50
Quaglini S. 15
Quintares R. 12
Quint T. 52
Rabani M. 42
Rabelink T.J. 46
Radbruch A. 13, 15, 31, 42, 43
Rademacher J.G. 51
Radic M. 45
Radi N. 49
Radstake T.R. 22, 42
Raffetti E. 39
Raffiotta F. 15
Rahman A. 14, 20, 25, 26, 29, 34, 43, 44, 46, 49, 50
Rajakaria R. 35, 50
Rajasekharan Nair R. 52
Ramirez G.A. 39
Ramoní V. 40
Ramsey-Goldman R. 45
Rana M. 53
Ranjar B. 42
Rauoach B. 42
Rawat A. 39, 53
Rednic S. 53
Regola F. 28
Reid S. 20
Reiseter S. 12
Rekvig O.P. 32
Renadineau Y. 12
Repa A. 48
Reynolds J. 49
Ribi C. 16, 25
Riccardi A. 36
Richards T. 29, 49
Richez C. 16, 24
Richter J. 41, 42, 44, 50
Riedel R. 42
Riemekasten G. 15, 43
Ripoll V. 25, 43
Rivera García N.A. 30
Röber N. 35
Robinson G. 41
Rodrigues M. 37, 40
Rodríguez Carrio J. 38, 51, 52
Roelofs J. 15
Rokutanda R. 52
Roman Ivorra J.A. 31, 32, 34, 41, 48
Romeo N. 40
Romero-Diaz J. 36
<table>
<thead>
<tr>
<th>Authors Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rönnblom L.  16, 20, 21, 31, 70</td>
</tr>
<tr>
<td>Rönnelid J.  33, 39</td>
</tr>
<tr>
<td>Rose S.  28</td>
</tr>
<tr>
<td>Rossato M.  42</td>
</tr>
<tr>
<td>Rossides M.  23</td>
</tr>
<tr>
<td>Rovere-Querini P.  39</td>
</tr>
<tr>
<td>Ruacho G.  33</td>
</tr>
<tr>
<td>Rúa-Figueroa I.  14, 23, 36, 49</td>
</tr>
<tr>
<td>Ruci D.  48</td>
</tr>
<tr>
<td>Rudolph S.  35</td>
</tr>
<tr>
<td>Ruffatti A.  40</td>
</tr>
<tr>
<td>Ruiz-Irastorza G.  24, 45</td>
</tr>
<tr>
<td>Ruiz Lucea M.E.  30</td>
</tr>
<tr>
<td>Sabbadini M.G.  40</td>
</tr>
<tr>
<td>Saccon F.  13, 28</td>
</tr>
<tr>
<td>Sae Lim V.S.  31</td>
</tr>
<tr>
<td>Saeki Y.  34</td>
</tr>
<tr>
<td>Safdar O.  47</td>
</tr>
<tr>
<td>Sahebari M.  31, 37, 44</td>
</tr>
<tr>
<td>Salimi J.  31</td>
</tr>
<tr>
<td>Salman-Monte T.C.  36</td>
</tr>
<tr>
<td>Salvarani C.  40</td>
</tr>
<tr>
<td>Salvesen K.Å.  40</td>
</tr>
<tr>
<td>Samuelsson I.  49</td>
</tr>
<tr>
<td>Sánchez A.  49</td>
</tr>
<tr>
<td>Sander O.  11</td>
</tr>
<tr>
<td>Sandling J.K.  20, 21</td>
</tr>
<tr>
<td>Santos Jorge I.  37</td>
</tr>
<tr>
<td>Santos M.J.  44</td>
</tr>
<tr>
<td>Sari E.S.D.  48</td>
</tr>
<tr>
<td>Scarcella C.  39</td>
</tr>
<tr>
<td>Scheffold A.  15, 43</td>
</tr>
<tr>
<td>Scherer H.U.  46</td>
</tr>
<tr>
<td>Scherlinger M.  24</td>
</tr>
<tr>
<td>Schiffeler R.M.  15</td>
</tr>
<tr>
<td>Schirmbeck L.A.  16</td>
</tr>
<tr>
<td>Schjom J.  33</td>
</tr>
<tr>
<td>Schmidtke L.  43</td>
</tr>
<tr>
<td>Schneider M.  12, 30, 41, 42, 44, 45, 50, 54, 69, 71</td>
</tr>
<tr>
<td>Schönauer T.  12</td>
</tr>
<tr>
<td>Schrempf L.E.  51</td>
</tr>
<tr>
<td>Schroedter M.  41, 42</td>
</tr>
<tr>
<td>Schulz-Knappe P.  30, 32, 33</td>
</tr>
<tr>
<td>Schwarting A.  14, 26, 43, 46, 48, 50, 69</td>
</tr>
<tr>
<td>Sebastiani G.D.  40</td>
</tr>
<tr>
<td>Seethalekshmy S.  52</td>
</tr>
<tr>
<td>Segura A.  12</td>
</tr>
<tr>
<td>Segura B.  14</td>
</tr>
<tr>
<td>Selmi C.F.  40</td>
</tr>
<tr>
<td>Seredkina N.  32</td>
</tr>
<tr>
<td>Sewerin P.  45</td>
</tr>
<tr>
<td>Sfikakis P.P.  38</td>
</tr>
<tr>
<td>Shaffu S.  44</td>
</tr>
<tr>
<td>Shapira E.  25</td>
</tr>
<tr>
<td>Shariati Sarabi Z.  37</td>
</tr>
<tr>
<td>Shochat T.  17</td>
</tr>
<tr>
<td>Shoenfeld Y.  23</td>
</tr>
<tr>
<td>Shummalieva-Ivanova V.  35</td>
</tr>
<tr>
<td>Shummalieva R.  35</td>
</tr>
<tr>
<td>Siddiquopoulos P.  17, 36, 48</td>
</tr>
<tr>
<td>Siekierka-Harreis M.  18, 41, 42</td>
</tr>
<tr>
<td>Sifuentes Giraldo W.A.  50, 51</td>
</tr>
<tr>
<td>Signorini V.  40</td>
</tr>
<tr>
<td>Silva L.  49</td>
</tr>
<tr>
<td>Simard J.  23</td>
</tr>
<tr>
<td>Simos P.  17</td>
</tr>
<tr>
<td>Singh S.  39, 53</td>
</tr>
<tr>
<td>Sinico R.A.  15</td>
</tr>
<tr>
<td>Sinigaglia L.  40</td>
</tr>
<tr>
<td>Sjöwall C.  14, 20, 21, 39, 46</td>
</tr>
<tr>
<td>Skogh T.  14, 39</td>
</tr>
<tr>
<td>Skomsvoil J.F.  40</td>
</tr>
<tr>
<td>Smolen J.  13, 27</td>
</tr>
<tr>
<td>Snyder M.R.  34</td>
</tr>
<tr>
<td>Söder F.  47</td>
</tr>
<tr>
<td>Sohn S.J.  47</td>
</tr>
<tr>
<td>Song S.T.  37</td>
</tr>
<tr>
<td>Son I.W.  37</td>
</tr>
<tr>
<td>Soukop T.  42</td>
</tr>
<tr>
<td>Sousa Ines L.P.  14, 26, 44</td>
</tr>
<tr>
<td>Specker C.  11, 21, 26, 44</td>
</tr>
<tr>
<td>Spiliotis G.  52</td>
</tr>
<tr>
<td>Spinelli F.R.  22, 31, 33, 34, 47</td>
</tr>
<tr>
<td>Spyrou G.  36, 48</td>
</tr>
<tr>
<td>Sreedharan S.  52</td>
</tr>
<tr>
<td>Stach C.  54</td>
</tr>
<tr>
<td>Stagnaro C.  45, 50</td>
</tr>
<tr>
<td>Steeg L.  32</td>
</tr>
<tr>
<td>Steri M.  21</td>
</tr>
<tr>
<td>Stervbo U.  43</td>
</tr>
<tr>
<td>Steuer A.  53</td>
</tr>
<tr>
<td>Stevanovic R.  50</td>
</tr>
<tr>
<td>Stojan G.  36</td>
</tr>
<tr>
<td>Stoll T.  44</td>
</tr>
<tr>
<td>Strøm E.H.  32, 37</td>
</tr>
<tr>
<td>Su J.  13</td>
</tr>
<tr>
<td>Suárez Díaz A.  38, 51, 52</td>
</tr>
<tr>
<td>Suda M.  52</td>
</tr>
<tr>
<td>Suh C.  33</td>
</tr>
<tr>
<td>Sun Y.  17</td>
</tr>
<tr>
<td>Sunmboye K.  44</td>
</tr>
<tr>
<td>Suri D.  39, 53</td>
</tr>
<tr>
<td>Svennungsson E.  13, 16, 19, 20, 21, 22, 29, 33, 39, 49, 51</td>
</tr>
<tr>
<td>Syvänen A.C.  20, 21</td>
</tr>
<tr>
<td>Szabó E.  41</td>
</tr>
<tr>
<td>Szabo M.  17</td>
</tr>
<tr>
<td>Szappanos A.  17</td>
</tr>
<tr>
<td>Szmyrka M.  42</td>
</tr>
<tr>
<td>Szteblich A.  42</td>
</tr>
</tbody>
</table>

**T**

Taddeo A.  13
Tamburello A.  40
Tambe B.  35
Tampe D.  35
Tani C.  40, 45, 50
Tanti G.  31
Taraborelli M.  42
Tarr T.  48
Tascik K.  37
Taulaigo A.V.  24, 26, 47
Tazi Mezalek Z.  49
Tchao N.  47
Teixeira V.  44
Tejera Segura B.  34, 44
Tekeoglu S.  33
Tektonidou M.  20, 22, 26, 38
Temesgen-Oyelakin Y.  47
Temiz Karadag D.  33
Templin L.  42
Ten Berge R.J.  15
Teng Y.K.O.  26, 46
Tentolouris N.  38
Terizaki M.  48
Tesch S.  15, 43
Teshigawara S.  34
Thaler F.S.  31
Thanei M.  25
Thiel A.  13
Thiyagarajan D.  32
Thumfart J.  31
Tilinca M.  20
Tincani A.  21, 28, 37, 38, 39, 40, 42, 48
Toes R.E.M.  46
Tomero E.  23, 49
Toms J.  42
Authors Index

Toro Dominguez D.  12
Torre Salaberri I.  30
Torrente-Segarra V.  36
Torres-Cisneros J.  23
Toubi E.  43
Tougorti M.  35, 41, 44, 45
Tomau Z.  13
Tomasi S.  33, 34
Tsang-A-Sjoe M.W.  15, 29
Tsokos G.C.  28
Tszij S.  34
Tummala R.  19, 52
Turchetti G.  50
Tuschen M.  32, 33
Tzanavari A.  38, 53

U
Ullum H.  35
Unger L.  35
Unterwalder N.  31
Uriarte E.  23, 49
Urowitz M.  12, 13, 40

V
Vachvanichsanong P.  53
Vadacca M.  40
Vadasz Z.  43
Vagelli R.  45, 50
Valentini G.  36
Valesini G.  22, 31, 33, 34, 47
Van Daele P.L.A.  46
Van Den Hoogen L.L.  22, 42
Van Den Wetering J.  15
Van Eijndhoven M.A.  15
Van Leeuw B.  27
Van Roon J.A.G.  22, 42
Van Vollenhoven R.  13, 18, 24, 28
Van Wijk F.  22
Varela García M.  47
Varela N.  25
Varriano V .  31
Vasconcelos C.  17, 27, 43
Vasilache A.  53
Vázquez Díaz M.  51
Vazquez-Mateo C.  28, 46
Vela P.  23
Vele P.  53
Velthuis E.  50
Vercellone P.G.  15
Verginis P.  21
Verkuilien S.M.  15
Vicens Bernabeu E.  31, 32, 34, 41, 48
Vicente M.  24, 47
Victorino R.  39
Vikerfors A.  39
Villalobos Sánchez L.  51
Visalli E.  40
Vissini G.  31
Vivaldelli E.  40
Voadzan S.  20
Vokurkova D.  42
Voll R.  18, 25, 30
Vordenbäumen S.  20, 41, 42
Voskuyl A.E.  15, 29, 49
Voss A.  41
Vsetecka D.  30

W
Wagner C.  28
Wallace D.J.  28
Wallenius M.  40
Walunas T.  45
Wang Q.  17
Wang X.  50
Wax S.  46
Weglarz M.  42
Weinmann-Menke J.  43, 48
Wenzel J.  70
Wermeling F.  47
Westra J.  30
Wetterö J.  14, 39
Wheeler L.M.  50
Wiechmann A.  42
Wiedemann A.  17
Wienke J.  22
Wilde B.  42, 43
Willers R.  44
William S.  51
Wincup C.  27, 29, 34, 43, 44, 49, 50
Winkler-Rohlfing B.  44
Wirestam L.  14
Witte T.  30
Witzke O.  42, 43
Wöhrle S.  52
Wojcik J.  12
Won S.Y.  37
Wong H.  47
Wormser U.  25
Wu Y.L.  21
Y
Yalkinoglu O.  46
Yavuz S.  37
Yazici A.  33
Yoshimura M.  34
Yu C.Y.  21
Yuraszeck T.  47
Z
Zacouris-Verweij W.  18
Zanella I.  30
Zatti S.  40
Zea Mendoza A.  49, 51
Zeher M.  48
Zeisberg M.  35, 39
Zen M.  13, 15
Zeng X.  17
Zentilin A.  39
Zhao J.  17
Zickert A.  21, 22, 33, 46
Zucht H.D.  30, 32, 33
Zuliani L.  40
Zychlinsky A.  42
SLEuro, the European Lupus Society pursues the following goals:

- BUILDING up a community of clinicians and researchers interested in SLE - Systemic Lupus Erythematosus at a European and international level, with special focus to engage younger physicians in the field
- PROMOTING and coordinating the organisation of research and educational meetings on SLE and related syndromes
- PROMOTING equal access to best standard of care for SLE patients across Europe
- FACILITATING research projects and clinical trials in SLE

**Why should I become a SLEuro member?**

SLEuro is a voluntary and non-political association with social and philanthropic purposes that promotes scientific research and information with regard to SLE and related syndromes. We welcome new applications for membership from individuals and institutions of any nationality who share its purposes. Members must work in the scientific sector, have a proven education and formation and shall exercise a professional activity as researchers, clinicians, nurses or healthcare professionals. Membership goes from January to December and until December 2019 it will be **FREE OF CHARGE**.

**How to become a SLEuro member**

If you’re not a SLEuro member and would like to become one, you should reach the registration desk and fill in the application form.
ACKNOWLEDGEMENTS

PLATINUM SPONSOR

GOLD SPONSOR

SILVER SPONSOR

SUPPORTERS

ABBVIE
BIOGEN
ELI LILLY
EUROIMMUN
F. HOFFMANN LA ROCHE LTD
JANSSEN-CILAG GMBH
PFIZER
SANOFI-AVENTIS DEUTSCHLAND GMBH
UCB BIOPHARMA